{
  "@context": "https://schema.org",
  "@type": "DataCatalogItem",
  "name": "Interface 5DYW_1",
  "description": "Protein-protein interaction interface between chains nan and nan",
  "identifier": "5DYW_1",
  "mainEntity": {
    "@context": "https://schema.org",
    "@type": "Protein",
    "@id": "#protein_5DYW",
    "dct:conformsTo": "https://bioschemas.org/profiles/Protein/0.11-RELEASE",
    "identifier": "5DYW",
    "name": "Protein 5DYW",
    "description": "Protein structure with PDB ID: 5DYW. Part of the ELIXIR 3D-BioInfo benchmark dataset. This protein participates in interface 5DYW_1 as a homodimer.",
    "url": "https://www.rcsb.org/structure/5DYW",
    "taxonomicRange": {
      "@type": "DefinedTerm",
      "name": "Homo sapiens",
      "inDefinedTermSet": "https://www.ncbi.nlm.nih.gov/taxonomy",
      "termCode": "9606",
      "url": "https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606"
    },
    "alternateName": [
      "PDB 5DYW",
      "Protein ID 5DYW"
    ],
    "hasRepresentation": [
      {
        "@type": "PropertyValue",
        "name": "PDB Structure",
        "value": "https://raw.githubusercontent.com/biofold/ppi-benchmark-fair/main/data/benchmark_pdb_format/5dyw_1.pdb.gz",
        "description": "Compressed PDB format structure file"
      },
      {
        "@type": "PropertyValue",
        "name": "mmCIF Structure",
        "value": "https://raw.githubusercontent.com/biofold/ppi-benchmark-fair/main/data/benchmark_mmcif_format/5dyw.cif.gz",
        "description": "Compressed mmCIF format structure file"
      },
      {
        "@type": "PropertyValue",
        "name": "PDB ID",
        "value": "5DYW",
        "description": "RCSB PDB identifier"
      }
    ],
    "additionalProperty": [
      {
        "@type": "PropertyValue",
        "name": "PDB_ID",
        "value": "5DYW",
        "description": "Protein Data Bank identifier (4 letters)"
      },
      {
        "@type": "PropertyValue",
        "name": "AssociatedInterface",
        "value": "5DYW_1",
        "description": "Interface this protein participates in"
      },
      {
        "@type": "PropertyValue",
        "name": "InterfaceSource",
        "value": "QSalign",
        "description": "Source of interface ID: QSalign"
      },
      {
        "@type": "PropertyValue",
        "name": "InterfaceChains",
        "value": "nan-nan",
        "description": "Chains involved in the interface"
      },
      {
        "@type": "PropertyValue",
        "name": "InterfaceClassification",
        "value": "Non-physiological",
        "description": "Classification of the associated interface"
      },
      {
        "@type": "PropertyValue",
        "name": "LabelInterfaceChains",
        "value": "A-B",
        "description": "Chains involved in the assembly interface"
      },
      {
        "@type": "PropertyValue",
        "name": "Gene",
        "value": "BCHE",
        "description": "Gene name associated with the protein"
      },
      {
        "@type": "PropertyValue",
        "name": "Superfamily",
        "value": "3.40.50.1820",
        "description": "Protein superfamily classification"
      },
      {
        "@type": "PropertyValue",
        "name": "Pfam",
        "value": "PF00135",
        "description": "Pfam domain classification"
      },
      {
        "@type": "PropertyValue",
        "name": "PDBStructureMetadata",
        "description": "Structural metadata from RCSB Protein Data Bank",
        "value": "{\"pdb_id\": \"5DYW\", \"structure_metadata\": {\"pdb_id\": \"5DYW\", \"resolution\": 2.5, \"deposition_date\": \"2015-09-25T00:00:00+0000\", \"release_date\": \"2017-01-18T00:00:00+0000\", \"experimental_method\": null, \"source_organism\": [\"Homo sapiens\"], \"citation\": {\"title\": \"Development of an in-vivo active reversible butyrylcholinesterase inhibitor.\", \"doi\": \"10.1038/srep39495\", \"authors\": [\"Kosak, U.\", \"Brus, B.\", \"Knez, D.\", \"Sink, R.\", \"Zakelj, S.\", \"Trontelj, J.\", \"Pislar, A.\", \"Slenc, J.\", \"Gobec, M.\", \"Zivin, M.\", \"Tratnjek, L.\", \"Perse, M.\", \"Saat, K.\", \"Podkowa, A.\", \"Filipek, B.\", \"Nachon, F.\", \"Brazzolotto, X.\", \"Wieckowska, A.\", \"Malawska, B.\", \"Stojan, J.\", \"Rascan, I.M.\", \"Kos, J.\", \"Coquelle, N.\", \"Colletier, J.P.\", \"Gobec, S.\"]}, \"entity_count\": 11, \"r_factor\": null, \"space_group\": null, \"unit_cell\": {\"a\": 72.214, \"b\": 78.863, \"c\": 226.65, \"alpha\": 90.0, \"beta\": 90.0, \"gamma\": 90.0}, \"found_in_api\": true, \"sequences\": {\"A\": \"TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV\", \"B\": \"TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV\"}, \"chain_info\": {\"A\": {\"entity_id\": \"1\", \"organism\": \"Homo sapiens\", \"sequence_length\": 530, \"polymer_type\": \"polypeptide(L)\", \"gene_name\": null}, \"B\": {\"entity_id\": \"1\", \"organism\": \"Homo sapiens\", \"sequence_length\": 530, \"polymer_type\": \"polypeptide(L)\", \"gene_name\": null}}, \"entity_info\": {\"1\": {\"entity_id\": \"1\", \"sequence\": \"TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV\", \"organism\": \"Homo sapiens\", \"taxonomy_id\": 9606, \"chain_ids\": [\"A\", \"B\"], \"polymer_type\": \"polypeptide(L)\", \"sequence_length\": 530, \"gene_name\": null, \"uniprot_ids\": [\"P06276\"]}}, \"is_homomer\": true, \"sequence_clusters\": [{\"sequence\": \"TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV\", \"entities\": [\"1\"], \"chain_count\": 2}], \"chain_ids\": [], \"entity_ids\": [\"1\", \"2\", \"3\", \"4\", \"5\", \"6\", \"7\", \"8\", \"9\", \"10\", \"11\"], \"polymer_composition\": \"protein/oligosaccharide\", \"homomer_type\": \"monomer\", \"homomer_chains\": 2, \"chain_count\": 2, \"unique_sequences\": 1, \"avg_sequence_length\": 530.0, \"min_sequence_length\": 530, \"max_sequence_length\": 530}, \"entity_metadata\": {\"1\": {\"entity_poly\": {\"nstd_linkage\": \"no\", \"nstd_monomer\": \"no\", \"pdbx_seq_one_letter_code\": \"TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV\", \"pdbx_seq_one_letter_code_can\": \"TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV\", \"pdbx_strand_id\": \"A,B\", \"rcsb_artifact_monomer_count\": 0, \"rcsb_conflict_count\": 0, \"rcsb_deletion_count\": 0, \"rcsb_entity_polymer_type\": \"Protein\", \"rcsb_insertion_count\": 0, \"rcsb_mutation_count\": 0, \"rcsb_non_std_monomer_count\": 0, \"rcsb_sample_sequence_length\": 530, \"type\": \"polypeptide(L)\"}, \"entity_src_gen\": [{\"gene_src_common_name\": \"Human\", \"host_org_common_name\": \"Fruit fly\", \"pdbx_alt_source_flag\": \"sample\", \"pdbx_beg_seq_num\": 1, \"pdbx_end_seq_num\": 530, \"pdbx_gene_src_gene\": \"BCHE, CHE1\", \"pdbx_gene_src_ncbi_taxonomy_id\": \"9606\", \"pdbx_gene_src_scientific_name\": \"Homo sapiens\", \"pdbx_host_org_ncbi_taxonomy_id\": \"7227\", \"pdbx_host_org_scientific_name\": \"Drosophila melanogaster\", \"pdbx_seq_type\": \"Biological sequence\", \"pdbx_src_id\": 1}], \"rcsb_cluster_flexibility\": {\"avg_rmsd\": 0.477, \"label\": \"No\", \"link\": \"http://pdbflex.org/cluster.html#!/3o9mA/16013/5dywA\", \"max_rmsd\": 0.925, \"provenance_code\": \"PDBFlex\"}, \"rcsb_cluster_membership\": [{\"cluster_id\": 4098, \"identity\": 100}, {\"cluster_id\": 571, \"identity\": 95}, {\"cluster_id\": 593, \"identity\": 90}, {\"cluster_id\": 837, \"identity\": 70}, {\"cluster_id\": 498, \"identity\": 50}, {\"cluster_id\": 224, \"identity\": 30}], \"rcsb_entity_host_organism\": [{\"beg_seq_num\": 1, \"end_seq_num\": 530, \"ncbi_common_names\": [\"Sophophora melanogaster\", \"fruit fly\"], \"ncbi_parent_scientific_name\": \"Eukaryota\", \"ncbi_scientific_name\": \"Drosophila melanogaster\", \"ncbi_taxonomy_id\": 7227, \"pdbx_src_id\": 1, \"provenance_source\": \"Primary Data\", \"scientific_name\": \"Drosophila melanogaster\", \"taxonomy_lineage\": [{\"depth\": 1, \"id\": \"131567\", \"name\": \"cellular organisms\"}, {\"depth\": 1, \"id\": \"131567\", \"name\": \"biota\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukaryota\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eucarya\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eucaryotae\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukarya\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukaryotae\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"eukaryotes\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"Opisthokonta\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"Fungi/Metazoa group\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"opisthokonts\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"Metazoa\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"Animalia\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"animals\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"metazoans\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"multicellular animals\"}, {\"depth\": 5, \"id\": \"6072\", \"name\": \"Eumetazoa\"}, {\"depth\": 6, \"id\": \"33213\", \"name\": \"Bilateria\"}, {\"depth\": 7, \"id\": \"33317\", \"name\": \"Protostomia\"}, {\"depth\": 8, \"id\": \"1206794\", \"name\": \"Ecdysozoa\"}, {\"depth\": 9, \"id\": \"88770\", \"name\": \"Panarthropoda\"}, {\"depth\": 10, \"id\": \"6656\", \"name\": \"Arthropoda\"}, {\"depth\": 10, \"id\": \"6656\", \"name\": \"arthropods\"}, {\"depth\": 11, \"id\": \"197563\", \"name\": \"Mandibulata\"}, {\"depth\": 11, \"id\": \"197563\", \"name\": \"mandibulates\"}, {\"depth\": 12, \"id\": \"197562\", \"name\": \"Pancrustacea\"}, {\"depth\": 13, \"id\": \"6960\", \"name\": \"Hexapoda\"}, {\"depth\": 13, \"id\": \"6960\", \"name\": \"hexapods\"}, {\"depth\": 14, \"id\": \"50557\", \"name\": \"Insecta\"}, {\"depth\": 14, \"id\": \"50557\", \"name\": \"insects\"}, {\"depth\": 14, \"id\": \"50557\", \"name\": \"true insects\"}, {\"depth\": 15, \"id\": \"85512\", \"name\": \"Dicondylia\"}, {\"depth\": 16, \"id\": \"7496\", \"name\": \"Pterygota\"}, {\"depth\": 16, \"id\": \"7496\", \"name\": \"winged insects\"}, {\"depth\": 17, \"id\": \"33340\", \"name\": \"Neoptera\"}, {\"depth\": 18, \"id\": \"33392\", \"name\": \"Endopterygota\"}, {\"depth\": 18, \"id\": \"33392\", \"name\": \"Holometabola\"}, {\"depth\": 19, \"id\": \"7147\", \"name\": \"Diptera\"}, {\"depth\": 19, \"id\": \"7147\", \"name\": \"flies\"}, {\"depth\": 20, \"id\": \"7203\", \"name\": \"Brachycera\"}, {\"depth\": 21, \"id\": \"43733\", \"name\": \"Muscomorpha\"}, {\"depth\": 21, \"id\": \"43733\", \"name\": \"Asilomorpha\"}, {\"depth\": 22, \"id\": \"480118\", \"name\": \"Eremoneura\"}, {\"depth\": 23, \"id\": \"480117\", \"name\": \"Cyclorrhapha\"}, {\"depth\": 24, \"id\": \"43738\", \"name\": \"Schizophora\"}, {\"depth\": 25, \"id\": \"43741\", \"name\": \"Acalyptratae\"}, {\"depth\": 26, \"id\": \"43746\", \"name\": \"Ephydroidea\"}, {\"depth\": 27, \"id\": \"7214\", \"name\": \"Drosophilidae\"}, {\"depth\": 27, \"id\": \"7214\", \"name\": \"pomace flies\"}, {\"depth\": 28, \"id\": \"43845\", \"name\": \"Drosophilinae\"}, {\"depth\": 29, \"id\": \"46877\", \"name\": \"Drosophilini\"}, {\"depth\": 30, \"id\": \"7215\", \"name\": \"Drosophila\"}, {\"depth\": 30, \"id\": \"7215\", \"name\": \"fruit flies\"}, {\"depth\": 30, \"id\": \"7215\", \"name\": \"fruit fly\"}, {\"depth\": 31, \"id\": \"32341\", \"name\": \"Sophophora\"}, {\"depth\": 32, \"id\": \"32346\", \"name\": \"melanogaster group\"}, {\"depth\": 33, \"id\": \"32351\", \"name\": \"melanogaster subgroup\"}, {\"depth\": 34, \"id\": \"7227\", \"name\": \"Drosophila melanogaster\"}, {\"depth\": 34, \"id\": \"7227\", \"name\": \"Sophophora melanogaster\"}, {\"depth\": 34, \"id\": \"7227\", \"name\": \"fruit fly\"}]}], \"rcsb_entity_source_organism\": [{\"beg_seq_num\": 1, \"common_name\": \"Human\", \"end_seq_num\": 530, \"ncbi_common_names\": [\"human\"], \"ncbi_parent_scientific_name\": \"Eukaryota\", \"ncbi_scientific_name\": \"Homo sapiens\", \"ncbi_taxonomy_id\": 9606, \"pdbx_src_id\": 1, \"provenance_source\": \"Primary Data\", \"scientific_name\": \"Homo sapiens\", \"source_type\": \"genetically engineered\", \"taxonomy_lineage\": [{\"depth\": 1, \"id\": \"131567\", \"name\": \"cellular organisms\"}, {\"depth\": 1, \"id\": \"131567\", \"name\": \"biota\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukaryota\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eucarya\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eucaryotae\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukarya\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukaryotae\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"eukaryotes\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"Opisthokonta\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"Fungi/Metazoa group\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"opisthokonts\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"Metazoa\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"Animalia\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"animals\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"metazoans\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"multicellular animals\"}, {\"depth\": 5, \"id\": \"6072\", \"name\": \"Eumetazoa\"}, {\"depth\": 6, \"id\": \"33213\", \"name\": \"Bilateria\"}, {\"depth\": 7, \"id\": \"33511\", \"name\": \"Deuterostomia\"}, {\"depth\": 7, \"id\": \"33511\", \"name\": \"deuterostomes\"}, {\"depth\": 8, \"id\": \"7711\", \"name\": \"Chordata\"}, {\"depth\": 8, \"id\": \"7711\", \"name\": \"chordates\"}, {\"depth\": 9, \"id\": \"89593\", \"name\": \"Craniata\"}, {\"depth\": 10, \"id\": \"7742\", \"name\": \"Vertebrata\"}, {\"depth\": 10, \"id\": \"7742\", \"name\": \"vertebrates\"}, {\"depth\": 11, \"id\": \"7776\", \"name\": \"Gnathostomata\"}, {\"depth\": 11, \"id\": \"7776\", \"name\": \"jawed vertebrates\"}, {\"depth\": 12, \"id\": \"117570\", \"name\": \"Teleostomi\"}, {\"depth\": 13, \"id\": \"117571\", \"name\": \"Euteleostomi\"}, {\"depth\": 13, \"id\": \"117571\", \"name\": \"bony vertebrates\"}, {\"depth\": 14, \"id\": \"8287\", \"name\": \"Sarcopterygii\"}, {\"depth\": 15, \"id\": \"1338369\", \"name\": \"Dipnotetrapodomorpha\"}, {\"depth\": 16, \"id\": \"32523\", \"name\": \"Tetrapoda\"}, {\"depth\": 16, \"id\": \"32523\", \"name\": \"tetrapods\"}, {\"depth\": 17, \"id\": \"32524\", \"name\": \"Amniota\"}, {\"depth\": 17, \"id\": \"32524\", \"name\": \"amniotes\"}, {\"depth\": 18, \"id\": \"40674\", \"name\": \"Mammalia\"}, {\"depth\": 18, \"id\": \"40674\", \"name\": \"mammals\"}, {\"depth\": 19, \"id\": \"32525\", \"name\": \"Theria\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"Eutheria\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"Placentalia\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"eutherian mammals\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"placental mammals\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"placentals\"}, {\"depth\": 21, \"id\": \"1437010\", \"name\": \"Boreoeutheria\"}, {\"depth\": 21, \"id\": \"1437010\", \"name\": \"Boreotheria\"}, {\"depth\": 22, \"id\": \"314146\", \"name\": \"Euarchontoglires\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"Primates\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"Primata\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"primate\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"primates\"}, {\"depth\": 24, \"id\": \"376913\", \"name\": \"Haplorrhini\"}, {\"depth\": 25, \"id\": \"314293\", \"name\": \"Simiiformes\"}, {\"depth\": 25, \"id\": \"314293\", \"name\": \"Anthropoidea\"}, {\"depth\": 26, \"id\": \"9526\", \"name\": \"Catarrhini\"}, {\"depth\": 27, \"id\": \"314295\", \"name\": \"Hominoidea\"}, {\"depth\": 27, \"id\": \"314295\", \"name\": \"ape\"}, {\"depth\": 27, \"id\": \"314295\", \"name\": \"apes\"}, {\"depth\": 28, \"id\": \"9604\", \"name\": \"Hominidae\"}, {\"depth\": 28, \"id\": \"9604\", \"name\": \"Pongidae\"}, {\"depth\": 28, \"id\": \"9604\", \"name\": \"great apes\"}, {\"depth\": 29, \"id\": \"207598\", \"name\": \"Homininae\"}, {\"depth\": 29, \"id\": \"207598\", \"name\": \"Homo/Pan/Gorilla group\"}, {\"depth\": 30, \"id\": \"9605\", \"name\": \"Homo\"}, {\"depth\": 30, \"id\": \"9605\", \"name\": \"humans\"}, {\"depth\": 31, \"id\": \"9606\", \"name\": \"Homo sapiens\"}, {\"depth\": 31, \"id\": \"9606\", \"name\": \"human\"}], \"rcsb_gene_name\": [{\"provenance_source\": \"Primary Data\", \"value\": \"BCHE\"}, {\"provenance_source\": \"Primary Data\", \"value\": \"CHE1\"}]}], \"rcsb_genomic_lineage\": [{\"depth\": 1, \"id\": \"9606:3\", \"name\": \"Chromosome 3\"}, {\"depth\": 0, \"id\": \"9606\", \"name\": \"Homo sapiens\"}, {\"depth\": 2, \"id\": \"9606:3:butyrylcholinesterase\", \"name\": \"butyrylcholinesterase\"}], \"rcsb_polymer_entity\": {\"formula_weight\": 59.759, \"pdbx_description\": \"Cholinesterase\", \"pdbx_ec\": \"3.1.1.8\", \"pdbx_number_of_molecules\": 2, \"rcsb_multiple_source_flag\": \"N\", \"rcsb_source_part_count\": 1, \"rcsb_source_taxonomy_count\": 1, \"src_method\": \"man\", \"rcsb_ec_lineage\": [{\"depth\": 1, \"id\": \"3\", \"name\": \"Hydrolases\"}, {\"depth\": 2, \"id\": \"3.1\", \"name\": \"Acting on ester bonds\"}, {\"depth\": 3, \"id\": \"3.1.1\", \"name\": \"Carboxylic-ester hydrolases\"}, {\"depth\": 4, \"id\": \"3.1.1.8\", \"name\": \"cholinesterase\"}], \"rcsb_macromolecular_names_combined\": [{\"name\": \"Cholinesterase\", \"provenance_code\": \"ECO:0000304\", \"provenance_source\": \"PDB Preferred Name\"}, {\"name\": \"Acylcholine acylhydrolase\", \"provenance_code\": \"ECO:0000303\", \"provenance_source\": \"PDB Synonym\"}, {\"name\": \"Butyrylcholine esterase\", \"provenance_code\": \"ECO:0000303\", \"provenance_source\": \"PDB Synonym\"}, {\"name\": \"Choline esterase II\", \"provenance_code\": \"ECO:0000303\", \"provenance_source\": \"PDB Synonym\"}, {\"name\": \"Pseudocholinesterase\", \"provenance_code\": \"ECO:0000303\", \"provenance_source\": \"PDB Synonym\"}], \"rcsb_enzyme_class_combined\": [{\"depth\": 4, \"ec\": \"3.1.1.8\", \"provenance_source\": \"PDB Primary Data\"}], \"rcsb_polymer_name_combined\": {\"names\": [\"Cholinesterase\"], \"provenance_source\": \"UniProt Name\"}}, \"rcsb_polymer_entity_align\": [{\"provenance_source\": \"SIFTS\", \"reference_database_accession\": \"P06276\", \"reference_database_name\": \"UniProt\", \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 530, \"ref_beg_seq_id\": 28}]}], \"rcsb_polymer_entity_annotation\": [{\"annotation_id\": \"GO:0003990\", \"name\": \"acetylcholinesterase activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0003990\", \"name\": \"acetylcholinesterase activity\"}, {\"id\": \"GO:0016788\", \"name\": \"hydrolase activity, acting on ester bonds\"}, {\"id\": \"GO:0004104\", \"name\": \"cholinesterase activity\"}, {\"id\": \"GO:0052689\", \"name\": \"carboxylic ester hydrolase activity\"}, {\"id\": \"GO:0016787\", \"name\": \"hydrolase activity\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"GO:0007612\", \"name\": \"learning\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0007610\", \"name\": \"behavior\"}, {\"id\": \"GO:0032501\", \"name\": \"multicellular organismal process\"}, {\"id\": \"GO:0003008\", \"name\": \"system process\"}, {\"id\": \"GO:0007612\", \"name\": \"learning\"}, {\"id\": \"GO:0007611\", \"name\": \"learning or memory\"}, {\"id\": \"GO:0050877\", \"name\": \"nervous system process\"}, {\"id\": \"GO:0050890\", \"name\": \"cognition\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}]}, {\"annotation_id\": \"GO:0001540\", \"name\": \"amyloid-beta binding\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0033218\", \"name\": \"amide binding\"}, {\"id\": \"GO:0001540\", \"name\": \"amyloid-beta binding\"}, {\"id\": \"GO:0005488\", \"name\": \"binding\"}, {\"id\": \"GO:0042277\", \"name\": \"peptide binding\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"IPR050654\", \"name\": \"Acetylcholinesterase-related enzymes\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR050654\", \"name\": \"Acetylcholinesterase-related enzymes\"}]}, {\"annotation_id\": \"IPR000997\", \"name\": \"Cholinesterase\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"depth\": 1, \"id\": \"IPR000997\", \"name\": \"Cholinesterase\"}]}, {\"annotation_id\": \"GO:0050783\", \"name\": \"cocaine metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0050783\", \"name\": \"cocaine metabolic process\"}]}, {\"annotation_id\": \"IPR002018\", \"name\": \"Carboxylesterase, type B\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR002018\", \"name\": \"Carboxylesterase, type B\"}]}, {\"annotation_id\": \"GO:0033265\", \"name\": \"choline binding\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0033265\", \"name\": \"choline binding\"}, {\"id\": \"GO:0043169\", \"name\": \"cation binding\"}, {\"id\": \"GO:0043167\", \"name\": \"ion binding\"}, {\"id\": \"GO:0005488\", \"name\": \"binding\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}, {\"id\": \"GO:0036094\", \"name\": \"small molecule binding\"}]}, {\"annotation_id\": \"GO:0005886\", \"name\": \"plasma membrane\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0071944\", \"name\": \"cell periphery\"}, {\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005886\", \"name\": \"plasma membrane\"}, {\"id\": \"GO:0016020\", \"name\": \"membrane\"}]}, {\"annotation_id\": \"IPR019819\", \"name\": \"Carboxylesterase type B, conserved site\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR019819\", \"name\": \"Carboxylesterase type B, conserved site\"}]}, {\"annotation_id\": \"GO:0016486\", \"name\": \"peptide hormone processing\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016486\", \"name\": \"peptide hormone processing\"}, {\"id\": \"GO:0010817\", \"name\": \"regulation of hormone levels\"}, {\"id\": \"GO:0065007\", \"name\": \"biological regulation\"}, {\"id\": \"GO:0140448\", \"name\": \"signaling receptor ligand precursor processing\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0010467\", \"name\": \"gene expression\"}, {\"id\": \"GO:0009059\", \"name\": \"macromolecule biosynthetic process\"}, {\"id\": \"GO:0042445\", \"name\": \"hormone metabolic process\"}, {\"id\": \"GO:0051604\", \"name\": \"protein maturation\"}, {\"id\": \"GO:0009058\", \"name\": \"biosynthetic process\"}, {\"id\": \"GO:0006508\", \"name\": \"proteolysis\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0016485\", \"name\": \"protein processing\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0043603\", \"name\": \"amide metabolic process\"}, {\"id\": \"GO:0019538\", \"name\": \"protein metabolic process\"}, {\"id\": \"GO:0043170\", \"name\": \"macromolecule metabolic process\"}, {\"id\": \"GO:0065008\", \"name\": \"regulation of biological quality\"}]}, {\"annotation_id\": \"GO:0051384\", \"name\": \"response to glucocorticoid\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0031960\", \"name\": \"response to corticosteroid\"}, {\"id\": \"GO:0033993\", \"name\": \"response to lipid\"}, {\"id\": \"GO:0050896\", \"name\": \"response to stimulus\"}, {\"id\": \"GO:0009725\", \"name\": \"response to hormone\"}, {\"id\": \"GO:0048545\", \"name\": \"response to steroid hormone\"}, {\"id\": \"GO:0042221\", \"name\": \"response to chemical\"}, {\"id\": \"GO:0009719\", \"name\": \"response to endogenous stimulus\"}, {\"id\": \"GO:0051384\", \"name\": \"response to glucocorticoid\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}]}, {\"annotation_id\": \"GO:0004104\", \"name\": \"cholinesterase activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016788\", \"name\": \"hydrolase activity, acting on ester bonds\"}, {\"id\": \"GO:0004104\", \"name\": \"cholinesterase activity\"}, {\"id\": \"GO:0052689\", \"name\": \"carboxylic ester hydrolase activity\"}, {\"id\": \"GO:0016787\", \"name\": \"hydrolase activity\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"GO:0006581\", \"name\": \"acetylcholine catabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0009056\", \"name\": \"catabolic process\"}, {\"id\": \"GO:0006581\", \"name\": \"acetylcholine catabolic process\"}, {\"id\": \"GO:0008291\", \"name\": \"acetylcholine metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}]}, {\"annotation_id\": \"GO:0072562\", \"name\": \"blood microparticle\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005576\", \"name\": \"extracellular region\"}, {\"id\": \"GO:0005615\", \"name\": \"extracellular space\"}, {\"id\": \"GO:0072562\", \"name\": \"blood microparticle\"}]}, {\"annotation_id\": \"GO:0005641\", \"name\": \"nuclear envelope lumen\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0043227\", \"name\": \"membrane-bounded organelle\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005622\", \"name\": \"intracellular anatomical structure\"}, {\"id\": \"GO:0005634\", \"name\": \"nucleus\"}, {\"id\": \"GO:0031974\", \"name\": \"membrane-enclosed lumen\"}, {\"id\": \"GO:0043231\", \"name\": \"intracellular membrane-bounded organelle\"}, {\"id\": \"GO:0012505\", \"name\": \"endomembrane system\"}, {\"id\": \"GO:0070013\", \"name\": \"intracellular organelle lumen\"}, {\"id\": \"GO:0031970\", \"name\": \"organelle envelope lumen\"}, {\"id\": \"GO:0043229\", \"name\": \"intracellular organelle\"}, {\"id\": \"GO:0031967\", \"name\": \"organelle envelope\"}, {\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0043233\", \"name\": \"organelle lumen\"}, {\"id\": \"GO:0043226\", \"name\": \"organelle\"}, {\"id\": \"GO:0005641\", \"name\": \"nuclear envelope lumen\"}, {\"id\": \"GO:0005635\", \"name\": \"nuclear envelope\"}]}, {\"annotation_id\": \"IPR019826\", \"name\": \"Carboxylesterase type B, active site\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR019826\", \"name\": \"Carboxylesterase type B, active site\"}]}, {\"annotation_id\": \"GO:0006805\", \"name\": \"xenobiotic metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0051716\", \"name\": \"cellular response to stimulus\"}, {\"id\": \"GO:0070887\", \"name\": \"cellular response to chemical stimulus\"}, {\"id\": \"GO:0050896\", \"name\": \"response to stimulus\"}, {\"id\": \"GO:0042221\", \"name\": \"response to chemical\"}, {\"id\": \"GO:0071466\", \"name\": \"cellular response to xenobiotic stimulus\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0006805\", \"name\": \"xenobiotic metabolic process\"}, {\"id\": \"GO:0009410\", \"name\": \"response to xenobiotic stimulus\"}]}, {\"annotation_id\": \"GO:0005788\", \"name\": \"endoplasmic reticulum lumen\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0043227\", \"name\": \"membrane-bounded organelle\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005622\", \"name\": \"intracellular anatomical structure\"}, {\"id\": \"GO:0031974\", \"name\": \"membrane-enclosed lumen\"}, {\"id\": \"GO:0043231\", \"name\": \"intracellular membrane-bounded organelle\"}, {\"id\": \"GO:0012505\", \"name\": \"endomembrane system\"}, {\"id\": \"GO:0070013\", \"name\": \"intracellular organelle lumen\"}, {\"id\": \"GO:0005788\", \"name\": \"endoplasmic reticulum lumen\"}, {\"id\": \"GO:0043229\", \"name\": \"intracellular organelle\"}, {\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0043233\", \"name\": \"organelle lumen\"}, {\"id\": \"GO:0043226\", \"name\": \"organelle\"}, {\"id\": \"GO:0005783\", \"name\": \"endoplasmic reticulum\"}, {\"id\": \"GO:0005737\", \"name\": \"cytoplasm\"}]}, {\"annotation_id\": \"GO:0005576\", \"name\": \"extracellular region\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005576\", \"name\": \"extracellular region\"}]}, {\"annotation_id\": \"GO:0008285\", \"name\": \"negative regulation of cell population proliferation\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0008285\", \"name\": \"negative regulation of cell population proliferation\"}, {\"id\": \"GO:0050789\", \"name\": \"regulation of biological process\"}, {\"id\": \"GO:0008283\", \"name\": \"cell population proliferation\"}, {\"id\": \"GO:0050794\", \"name\": \"regulation of cellular process\"}, {\"id\": \"GO:0042127\", \"name\": \"regulation of cell population proliferation\"}, {\"id\": \"GO:0048523\", \"name\": \"negative regulation of cellular process\"}, {\"id\": \"GO:0065007\", \"name\": \"biological regulation\"}, {\"id\": \"GO:0048519\", \"name\": \"negative regulation of biological process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}]}, {\"annotation_id\": \"GO:0014016\", \"name\": \"neuroblast differentiation\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0032502\", \"name\": \"developmental process\"}, {\"id\": \"GO:0032501\", \"name\": \"multicellular organismal process\"}, {\"id\": \"GO:0048869\", \"name\": \"cellular developmental process\"}, {\"id\": \"GO:0014016\", \"name\": \"neuroblast differentiation\"}, {\"id\": \"GO:0007399\", \"name\": \"nervous system development\"}, {\"id\": \"GO:0048699\", \"name\": \"generation of neurons\"}, {\"id\": \"GO:0022008\", \"name\": \"neurogenesis\"}, {\"id\": \"GO:0007275\", \"name\": \"multicellular organism development\"}, {\"id\": \"GO:0030154\", \"name\": \"cell differentiation\"}, {\"id\": \"GO:0048856\", \"name\": \"anatomical structure development\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0048731\", \"name\": \"system development\"}]}, {\"annotation_id\": \"GO:0050805\", \"name\": \"negative regulation of synaptic transmission\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0099537\", \"name\": \"trans-synaptic signaling\"}, {\"id\": \"GO:0023051\", \"name\": \"regulation of signaling\"}, {\"id\": \"GO:0050789\", \"name\": \"regulation of biological process\"}, {\"id\": \"GO:0050794\", \"name\": \"regulation of cellular process\"}, {\"id\": \"GO:0023057\", \"name\": \"negative regulation of signaling\"}, {\"id\": \"GO:0023052\", \"name\": \"signaling\"}, {\"id\": \"GO:0050804\", \"name\": \"modulation of chemical synaptic transmission\"}, {\"id\": \"GO:0065007\", \"name\": \"biological regulation\"}, {\"id\": \"GO:0048519\", \"name\": \"negative regulation of biological process\"}, {\"id\": \"GO:0007267\", \"name\": \"cell-cell signaling\"}, {\"id\": \"GO:0050805\", \"name\": \"negative regulation of synaptic transmission\"}, {\"id\": \"GO:0010648\", \"name\": \"negative regulation of cell communication\"}, {\"id\": \"GO:0007154\", \"name\": \"cell communication\"}, {\"id\": \"GO:0007268\", \"name\": \"chemical synaptic transmission\"}, {\"id\": \"GO:0099536\", \"name\": \"synaptic signaling\"}, {\"id\": \"GO:0099177\", \"name\": \"regulation of trans-synaptic signaling\"}, {\"id\": \"GO:0098916\", \"name\": \"anterograde trans-synaptic signaling\"}, {\"id\": \"GO:0048523\", \"name\": \"negative regulation of cellular process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0010646\", \"name\": \"regulation of cell communication\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}]}, {\"annotation_id\": \"IPR029058\", \"name\": \"Alpha/Beta hydrolase fold\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR029058\", \"name\": \"Alpha/Beta hydrolase fold\"}]}, {\"annotation_id\": \"GO:0003824\", \"name\": \"catalytic activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"GO:0019695\", \"name\": \"choline metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0019695\", \"name\": \"choline metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}]}, {\"annotation_id\": \"GO:0043279\", \"name\": \"response to alkaloid\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0050896\", \"name\": \"response to stimulus\"}, {\"id\": \"GO:0042221\", \"name\": \"response to chemical\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:1901698\", \"name\": \"response to nitrogen compound\"}, {\"id\": \"GO:0043279\", \"name\": \"response to alkaloid\"}]}, {\"annotation_id\": \"GO:0051593\", \"name\": \"response to folic acid\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0031667\", \"name\": \"response to nutrient levels\"}, {\"id\": \"GO:0050896\", \"name\": \"response to stimulus\"}, {\"id\": \"GO:0042221\", \"name\": \"response to chemical\"}, {\"id\": \"GO:0051593\", \"name\": \"response to folic acid\"}, {\"id\": \"GO:0007584\", \"name\": \"response to nutrient\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:1901700\", \"name\": \"response to oxygen-containing compound\"}, {\"id\": \"GO:1901698\", \"name\": \"response to nitrogen compound\"}, {\"id\": \"GO:0033273\", \"name\": \"response to vitamin\"}]}, {\"annotation_id\": \"GO:0016788\", \"name\": \"hydrolase activity, acting on ester bonds\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016788\", \"name\": \"hydrolase activity, acting on ester bonds\"}, {\"id\": \"GO:0016787\", \"name\": \"hydrolase activity\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"GO:0005615\", \"name\": \"extracellular space\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005576\", \"name\": \"extracellular region\"}, {\"id\": \"GO:0005615\", \"name\": \"extracellular space\"}]}, {\"annotation_id\": \"IPR014788\", \"name\": \"Acetylcholinesterase, tetramerisation domain\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR014788\", \"name\": \"Acetylcholinesterase, tetramerisation domain\"}]}, {\"annotation_id\": \"GO:0019899\", \"name\": \"enzyme binding\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0005515\", \"name\": \"protein binding\"}, {\"id\": \"GO:0005488\", \"name\": \"binding\"}, {\"id\": \"GO:0019899\", \"name\": \"enzyme binding\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"GO:0042802\", \"name\": \"identical protein binding\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0042802\", \"name\": \"identical protein binding\"}, {\"id\": \"GO:0005515\", \"name\": \"protein binding\"}, {\"id\": \"GO:0005488\", \"name\": \"binding\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}], \"rcsb_polymer_entity_container_identifiers\": {\"asym_ids\": [\"A\", \"B\"], \"auth_asym_ids\": [\"A\", \"B\"], \"chem_comp_monomers\": [\"ALA\", \"ARG\", \"ASN\", \"ASP\", \"CYS\", \"GLN\", \"GLU\", \"GLY\", \"HIS\", \"ILE\", \"LEU\", \"LYS\", \"MET\", \"PHE\", \"PRO\", \"SER\", \"THR\", \"TRP\", \"TYR\", \"VAL\"], \"entity_id\": \"1\", \"entry_id\": \"5DYW\", \"rcsb_id\": \"5DYW_1\", \"uniprot_ids\": [\"P06276\"], \"reference_sequence_identifiers\": [{\"database_accession\": \"P06276\", \"database_name\": \"UniProt\", \"entity_sequence_coverage\": 1.0, \"provenance_source\": \"SIFTS\", \"reference_sequence_coverage\": 0.8803986710963455}]}, \"rcsb_polymer_entity_feature\": [{\"name\": \"Hydropathy values\", \"provenance_source\": \"biojava-7.2.4\", \"type\": \"hydropathy\", \"feature_positions\": [{\"beg_seq_id\": 5, \"values\": [0.38, 0.02, 0.02, 0.37, 0.32, 0.29, -0.71, -1.26, -1.24, -1.56, -0.7, -0.39, 0.12, 0.87, 0.36, 0.81, 0.78, 1.03, 1.34, 1.12, 1.51, 1.47, 1.11, 1.66, 1.52, 1.46, 1.19, 0.88, 0.5, 0.01, 0.01, 0.01, -0.99, -0.39, -0.74, -0.63, -0.68, -0.93, -0.93, -1.74, -1.79, -0.87, -1.37, -1.3, -1.71, -1.37, -1.32, -0.64, -0.36, -0.66, -0.88, -0.88, -0.88, -0.92, -0.63, -0.63, -1.22, -0.84, -0.18, -0.77, -1.08, -0.14, -0.39, -0.98, -0.68, -0.28, -0.73, -1.06, -0.36, -0.32, -0.87, -0.57, -0.57, -0.27, -0.68, -0.89, -1.02, -1.72, -1.44, -1.79, -1.28, -0.98, -1.58, -1.87, -1.2, -0.6, -0.36, 0.14, 0.14, 0.19, 0.18, 1.07, 1.28, 1.2, 0.6, 0.31, -0.29, -0.33, -1.19, -0.89, -1.47, -0.82, -0.6, 0.08, 0.41, 1.09, 1.38, 1.72, 1.48, 1.51, 1.36, 0.54, -0.03, 0.02, -0.56, -0.5, -0.54, -0.08, -0.39, -0.23, 0.01, -0.3, -0.3, -0.66, -0.26, 0.26, 0.03, -0.11, -0.11, -0.36, -0.47, 0.04, 0.98, 1.13, 1.18, 0.89, 1.6, 0.74, 0.99, 0.99, 0.99, 0.44, 0.18, 0.13, 0.18, 0.28, 1.09, 1.43, 2.36, 1.71, 1.71, 1.12, 0.52, 0.18, 0.07, -0.53, -0.78, -1.59, -1.2, -1.2, -0.39, 0.1, 0.1, -0.49, -0.7, -0.23, 0.36, 0.57, 0.22, -0.3, -0.14, -0.14, -0.19, -0.19, -0.11, -0.11, -0.33, 0.37, 0.42, -0.09, -0.09, 0.17, 0.12, -0.47, -0.2, -0.48, -0.37, -0.01, -0.01, -0.01, 0.08, 0.71, 0.76, 0.49, 0.77, 0.26, 0.41, 0.37, 1.18, 0.91, 1.13, 1.6, 1.31, 0.93, 0.98, 0.42, 0.16, -0.36, 0.42, 0.31, -0.19, -0.6, -0.22, 0.32, 0.83, 0.8, 0.8, 0.33, -0.07, 0.32, 0.43, 0.43, -0.24, -0.77, -0.18, 0.38, 0.34, 0.34, 0.46, 0.7, 0.11, 0.49, 0.09, -0.5, -1.47, -1.47, -0.96, -1.77, -1.2, -0.61, -1.24, -0.32, -0.01, 0.44, 0.8, 0.29, 0.18, -0.63, -1.22, -1.18, -1.68, -1.99, -1.44, -1.22, -1.57, -0.79, 0.02, -0.09, -0.09, -0.44, -0.44, -1.12, -2.01, -1.97, -1.74, -1.74, -0.82, -0.82, -0.78, -0.19, 0.3, 1.16, 2.01, 1.33, 0.77, 0.3, 0.61, 0.82, 1.04, 0.64, 0.64, -0.21, 0.28, 0.38, 0.24, 0.24, 0.89, 0.08, 0.12, -0.73, -0.03, 0.08, 0.04, -0.17, 0.12, -0.52, -0.52, 0.02, 0.83, 0.94, 0.13, 0.63, 0.98, 0.38, 0.87, 0.82, -0.11, -0.61, -1.42, -0.53, -0.53, -0.02, 0.32, 0.48, 0.52, 0.52, 0.21, 0.21, -0.33, -0.83, -1.1, -0.74, -0.79, 0.07, 0.36, 0.7, 1.29, 1.16, 1.19, 1.3, 0.9, 0.04, -0.81, -1.06, -1.4, -1.69, -1.01, -0.47, -0.86, -1.27, -1.27, -1.27, -0.57, -0.57, -0.87, -1.41, -1.49, -1.84, -0.84, -0.1, 0.6, 0.11, 0.46, 1.31, 1.27, 0.46, 1.2, 0.66, -0.09, -0.79, -0.7, -0.16, -0.2, 0.2, 0.23, -0.22, -0.26, -0.21, 0.08, 0.63, -0.26, -1.07, -1.77, -1.91, -1.94, -2.26, -2.26, -2.3, -3.27, -3.27, -2.68, -1.87, -1.41, -1.62, -0.77, 0.09, 0.19, 0.3, 0.54, -0.04, -0.16, 0.39, 1.06, 0.41, 0.14, 0.61, 0.61, 1.07, 1.38, 0.63, -0.3, -0.27, -0.18, -0.77, -1.29, -0.94, -1.64, -1.96, -1.32, -0.58, -0.58, -0.63, -0.39, 0.02, -0.32, -0.29, -0.4, -0.69, -1.09, -1.83, -1.27, -1.3, -1.71, -1.5, -1.53, -1.13, -0.83, -0.79, 0.11, -0.1, -0.28, -0.22, -0.19, -0.19, 0.41, -0.19, 0.17, 0.17, 0.27, 0.58, 1.04, 1.01, 1.82, 0.93, 0.82, 0.01, -0.84, -1.54, -1.64, -2.14, -2.4, -2.62, -2.62, -2.51, -1.51, -0.7, -0.4, -0.76, -0.77, 0.17, 0.43, 0.39, 0.28, -0.32, -0.54, -0.84, -0.03, 0.26, -0.68, -1.29, -0.9, -0.79, -0.87, -1.46, -1.46, -1.84, -2.43, -2.39, -2.63, -2.68, -2.37, -2.28, -1.99, -1.78, -1.23, -0.53, -0.58, -0.28, -0.27, -0.58, -0.88, -1.21, -1.18, -1.22, -1.61, -0.76, -1.06, -1.06, -1.06, -0.76, -0.4, -0.76, -0.68, -0.39, -0.89, -0.93, -0.43, -0.54, -0.26, -0.57, -0.46, -0.68, -1.39, -1.0, -0.67, -1.17, -0.76, -0.64, 0.06, 0.27, -0.44, 0.52]}]}, {\"name\": \"Disordered regions\", \"provenance_source\": \"IUPred2(short)\", \"type\": \"disorder\", \"feature_positions\": [{\"beg_seq_id\": 1, \"values\": [0.8, 0.76, 0.71, 0.61, 0.58, 0.53, 0.46, 0.41, 0.28, 0.24, 0.15, 0.1, 0.09, 0.1, 0.1, 0.1, 0.15, 0.19, 0.15, 0.1, 0.11, 0.07, 0.08, 0.05, 0.06, 0.07, 0.08, 0.12, 0.07, 0.12, 0.12, 0.12, 0.18, 0.12, 0.12, 0.11, 0.18, 0.19, 0.22, 0.23, 0.3, 0.29, 0.3, 0.27, 0.37, 0.34, 0.25, 0.23, 0.18, 0.25, 0.26, 0.18, 0.23, 0.23, 0.31, 0.25, 0.2, 0.19, 0.18, 0.15, 0.21, 0.23, 0.22, 0.22, 0.24, 0.23, 0.2, 0.24, 0.24, 0.26, 0.27, 0.23, 0.25, 0.27, 0.29, 0.29, 0.34, 0.41, 0.31, 0.31, 0.38, 0.38, 0.32, 0.24, 0.24, 0.15, 0.15, 0.17, 0.14, 0.1, 0.12, 0.09, 0.12, 0.16, 0.18, 0.16, 0.16, 0.13, 0.12, 0.13, 0.09, 0.05, 0.03, 0.02, 0.02, 0.04, 0.05, 0.05, 0.04, 0.06, 0.1, 0.08, 0.1, 0.09, 0.09, 0.05, 0.05, 0.03, 0.02, 0.02, 0.03, 0.05, 0.04, 0.04, 0.05, 0.09, 0.05, 0.06, 0.06, 0.09, 0.05, 0.04, 0.02, 0.02, 0.02, 0.02, 0.02, 0.02, 0.02, 0.03, 0.02, 0.01, 0.01, 0.01, 0.01, 0.02, 0.01, 0.02, 0.02, 0.02, 0.03, 0.06, 0.06, 0.12, 0.11, 0.15, 0.12, 0.18, 0.12, 0.12, 0.13, 0.17, 0.27, 0.19, 0.26, 0.27, 0.32, 0.36, 0.27, 0.28, 0.27, 0.25, 0.17, 0.18, 0.13, 0.08, 0.08, 0.11, 0.11, 0.19, 0.27, 0.26, 0.17, 0.16, 0.16, 0.12, 0.18, 0.18, 0.22, 0.26, 0.24, 0.21, 0.18, 0.24, 0.2, 0.23, 0.23, 0.24, 0.17, 0.11, 0.09, 0.1, 0.1, 0.15, 0.15, 0.21, 0.22, 0.14, 0.13, 0.13, 0.13, 0.09, 0.06, 0.09, 0.09, 0.13, 0.13, 0.12, 0.12, 0.14, 0.23, 0.16, 0.12, 0.08, 0.09, 0.09, 0.06, 0.06, 0.11, 0.09, 0.09, 0.1, 0.15, 0.22, 0.15, 0.15, 0.11, 0.09, 0.16, 0.11, 0.13, 0.11, 0.12, 0.14, 0.18, 0.18, 0.18, 0.26, 0.33, 0.33, 0.29, 0.22, 0.22, 0.15, 0.1, 0.15, 0.15, 0.19, 0.23, 0.26, 0.33, 0.35, 0.28, 0.3, 0.23, 0.23, 0.24, 0.22, 0.15, 0.12, 0.08, 0.14, 0.15, 0.15, 0.22, 0.32, 0.24, 0.24, 0.18, 0.17, 0.1, 0.1, 0.11, 0.16, 0.14, 0.21, 0.21, 0.21, 0.16, 0.15, 0.19, 0.27, 0.19, 0.3, 0.31, 0.23, 0.14, 0.15, 0.16, 0.15, 0.15, 0.23, 0.15, 0.11, 0.11, 0.16, 0.16, 0.11, 0.06, 0.07, 0.12, 0.08, 0.07, 0.09, 0.08, 0.08, 0.13, 0.18, 0.23, 0.14, 0.15, 0.1, 0.06, 0.11, 0.09, 0.12, 0.13, 0.07, 0.11, 0.15, 0.22, 0.22, 0.29, 0.28, 0.22, 0.15, 0.14, 0.13, 0.13, 0.17, 0.16, 0.24, 0.32, 0.4, 0.31, 0.33, 0.23, 0.16, 0.18, 0.21, 0.22, 0.15, 0.15, 0.16, 0.11, 0.16, 0.21, 0.23, 0.23, 0.18, 0.12, 0.12, 0.11, 0.06, 0.06, 0.12, 0.07, 0.07, 0.12, 0.18, 0.17, 0.15, 0.23, 0.25, 0.24, 0.23, 0.21, 0.24, 0.2, 0.13, 0.2, 0.27, 0.28, 0.22, 0.29, 0.31, 0.2, 0.29, 0.27, 0.18, 0.12, 0.13, 0.13, 0.07, 0.06, 0.04, 0.06, 0.06, 0.05, 0.03, 0.05, 0.06, 0.03, 0.05, 0.07, 0.07, 0.05, 0.05, 0.03, 0.03, 0.02, 0.02, 0.02, 0.01, 0.02, 0.02, 0.04, 0.03, 0.02, 0.03, 0.02, 0.03, 0.03, 0.03, 0.02, 0.02, 0.01, 0.01, 0.02, 0.03, 0.03, 0.06, 0.07, 0.07, 0.05, 0.04, 0.02, 0.03, 0.02, 0.04, 0.02, 0.04, 0.03, 0.02, 0.05, 0.07, 0.04, 0.06, 0.08, 0.08, 0.08, 0.14, 0.09, 0.1, 0.09, 0.15, 0.19, 0.2, 0.15, 0.21, 0.19, 0.2, 0.18, 0.2, 0.16, 0.14, 0.14, 0.16, 0.16, 0.17, 0.21, 0.22, 0.21, 0.28, 0.35, 0.35, 0.37, 0.37, 0.44, 0.49, 0.42, 0.45, 0.47, 0.43, 0.43, 0.49, 0.5, 0.5, 0.57, 0.56, 0.49, 0.41, 0.4, 0.35, 0.35, 0.34, 0.34, 0.33, 0.33, 0.33, 0.27, 0.32, 0.29, 0.34, 0.32, 0.32, 0.3, 0.3, 0.31, 0.24, 0.25, 0.24, 0.21, 0.21, 0.26, 0.17, 0.11, 0.13, 0.13, 0.1, 0.12, 0.2, 0.27, 0.32, 0.36, 0.48, 0.52, 0.59, 0.63, 0.67]}]}, {\"name\": \"Disordered binding sites\", \"provenance_source\": \"Anchor2\", \"type\": \"disorder_binding\", \"feature_positions\": [{\"beg_seq_id\": 1, \"values\": [0.34, 0.33, 0.33, 0.33, 0.33, 0.33, 0.33, 0.32, 0.32, 0.31, 0.31, 0.32, 0.33, 0.34, 0.34, 0.35, 0.35, 0.34, 0.35, 0.37, 0.38, 0.4, 0.4, 0.4, 0.4, 0.41, 0.42, 0.43, 0.42, 0.43, 0.43, 0.43, 0.41, 0.42, 0.42, 0.41, 0.41, 0.4, 0.39, 0.39, 0.39, 0.39, 0.4, 0.4, 0.4, 0.4, 0.41, 0.41, 0.42, 0.43, 0.43, 0.43, 0.43, 0.42, 0.4, 0.39, 0.37, 0.33, 0.3, 0.27, 0.25, 0.23, 0.22, 0.21, 0.21, 0.2, 0.21, 0.22, 0.24, 0.25, 0.26, 0.27, 0.29, 0.31, 0.31, 0.32, 0.33, 0.32, 0.31, 0.31, 0.31, 0.31, 0.3, 0.28, 0.25, 0.24, 0.22, 0.22, 0.22, 0.22, 0.22, 0.22, 0.21, 0.22, 0.24, 0.25, 0.26, 0.27, 0.27, 0.25, 0.23, 0.22, 0.21, 0.2, 0.19, 0.17, 0.16, 0.16, 0.15, 0.14, 0.15, 0.15, 0.15, 0.14, 0.13, 0.13, 0.13, 0.14, 0.14, 0.13, 0.13, 0.13, 0.13, 0.13, 0.14, 0.14, 0.13, 0.13, 0.12, 0.12, 0.12, 0.11, 0.11, 0.11, 0.11, 0.11, 0.1, 0.1, 0.1, 0.1, 0.09, 0.09, 0.08, 0.08, 0.08, 0.08, 0.08, 0.08, 0.08, 0.09, 0.1, 0.12, 0.13, 0.15, 0.16, 0.18, 0.19, 0.21, 0.21, 0.22, 0.24, 0.24, 0.24, 0.24, 0.23, 0.23, 0.23, 0.24, 0.24, 0.25, 0.26, 0.26, 0.26, 0.26, 0.26, 0.26, 0.26, 0.27, 0.26, 0.25, 0.25, 0.24, 0.23, 0.23, 0.24, 0.24, 0.24, 0.25, 0.25, 0.26, 0.27, 0.27, 0.28, 0.29, 0.3, 0.3, 0.29, 0.28, 0.28, 0.27, 0.26, 0.26, 0.26, 0.25, 0.25, 0.24, 0.25, 0.26, 0.27, 0.28, 0.28, 0.3, 0.31, 0.33, 0.35, 0.36, 0.37, 0.38, 0.38, 0.38, 0.38, 0.38, 0.38, 0.38, 0.37, 0.37, 0.38, 0.39, 0.39, 0.4, 0.41, 0.41, 0.4, 0.4, 0.39, 0.39, 0.39, 0.37, 0.36, 0.34, 0.33, 0.32, 0.31, 0.31, 0.31, 0.31, 0.3, 0.29, 0.29, 0.28, 0.28, 0.27, 0.26, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.26, 0.26, 0.26, 0.26, 0.27, 0.28, 0.29, 0.29, 0.3, 0.32, 0.34, 0.35, 0.38, 0.41, 0.43, 0.42, 0.41, 0.4, 0.38, 0.37, 0.37, 0.37, 0.38, 0.39, 0.41, 0.42, 0.43, 0.42, 0.41, 0.39, 0.38, 0.38, 0.37, 0.37, 0.38, 0.39, 0.4, 0.41, 0.43, 0.41, 0.4, 0.39, 0.39, 0.38, 0.39, 0.4, 0.42, 0.43, 0.41, 0.37, 0.34, 0.31, 0.28, 0.25, 0.22, 0.21, 0.2, 0.19, 0.18, 0.18, 0.18, 0.18, 0.18, 0.19, 0.19, 0.21, 0.22, 0.23, 0.24, 0.25, 0.25, 0.25, 0.25, 0.24, 0.23, 0.23, 0.22, 0.21, 0.2, 0.18, 0.17, 0.17, 0.17, 0.18, 0.18, 0.19, 0.19, 0.19, 0.19, 0.21, 0.23, 0.25, 0.26, 0.27, 0.28, 0.3, 0.31, 0.32, 0.33, 0.33, 0.32, 0.31, 0.3, 0.29, 0.29, 0.28, 0.27, 0.27, 0.27, 0.28, 0.29, 0.3, 0.31, 0.3, 0.3, 0.29, 0.28, 0.27, 0.25, 0.22, 0.19, 0.17, 0.15, 0.14, 0.14, 0.13, 0.13, 0.13, 0.13, 0.13, 0.13, 0.14, 0.15, 0.15, 0.16, 0.16, 0.16, 0.15, 0.16, 0.16, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11, 0.1, 0.09, 0.09, 0.09, 0.09, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.16, 0.15, 0.13, 0.12, 0.1, 0.08, 0.07, 0.07, 0.07, 0.06, 0.06, 0.06, 0.06, 0.06, 0.07, 0.07, 0.08, 0.09, 0.09, 0.1, 0.12, 0.13, 0.15, 0.17, 0.2, 0.22, 0.24, 0.26, 0.27, 0.26, 0.26, 0.25, 0.23, 0.22, 0.21, 0.2, 0.21, 0.21, 0.21, 0.23, 0.25, 0.28, 0.3, 0.32, 0.35, 0.37, 0.38, 0.4, 0.41, 0.43, 0.42, 0.42, 0.42, 0.42, 0.42, 0.43, 0.42, 0.4, 0.38, 0.36, 0.33, 0.31, 0.3, 0.28, 0.27, 0.28, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.35, 0.36, 0.38, 0.39, 0.37, 0.36, 0.34, 0.33, 0.32, 0.31, 0.31, 0.31, 0.3, 0.3, 0.3, 0.3, 0.32, 0.33, 0.35, 0.37, 0.4, 0.41, 0.43, 0.42, 0.39, 0.37, 0.35, 0.33, 0.31, 0.29, 0.27, 0.25, 0.25, 0.25, 0.24, 0.24, 0.23, 0.23, 0.23, 0.23]}]}], \"rcsb_polymer_entity_group_membership\": [{\"aggregation_method\": \"sequence_identity\", \"group_id\": \"837_70\", \"similarity_cutoff\": 70.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 530, \"ref_beg_seq_id\": 29}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"571_95\", \"similarity_cutoff\": 95.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 530, \"ref_beg_seq_id\": 28}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"4098_100\", \"similarity_cutoff\": 100.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 530, \"ref_beg_seq_id\": 28}]}, {\"aggregation_method\": \"matching_uniprot_accession\", \"group_id\": \"P06276\", \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 530, \"ref_beg_seq_id\": 28}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"498_50\", \"similarity_cutoff\": 50.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 23, \"ref_beg_seq_id\": 35}, {\"entity_beg_seq_id\": 24, \"length\": 81, \"ref_beg_seq_id\": 59}, {\"entity_beg_seq_id\": 105, \"length\": 151, \"ref_beg_seq_id\": 141}, {\"entity_beg_seq_id\": 256, \"length\": 157, \"ref_beg_seq_id\": 296}, {\"entity_beg_seq_id\": 413, \"length\": 74, \"ref_beg_seq_id\": 483}, {\"entity_beg_seq_id\": 487, \"length\": 44, \"ref_beg_seq_id\": 561}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"224_30\", \"similarity_cutoff\": 30.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 20, \"ref_beg_seq_id\": 201}, {\"entity_beg_seq_id\": 21, \"length\": 2, \"ref_beg_seq_id\": 224}, {\"entity_beg_seq_id\": 23, \"length\": 28, \"ref_beg_seq_id\": 230}, {\"entity_beg_seq_id\": 51, \"length\": 3, \"ref_beg_seq_id\": 260}, {\"entity_beg_seq_id\": 54, \"length\": 2, \"ref_beg_seq_id\": 264}, {\"entity_beg_seq_id\": 56, \"length\": 21, \"ref_beg_seq_id\": 268}, {\"entity_beg_seq_id\": 77, \"length\": 2, \"ref_beg_seq_id\": 290}, {\"entity_beg_seq_id\": 79, \"length\": 8, \"ref_beg_seq_id\": 293}, {\"entity_beg_seq_id\": 87, \"length\": 15, \"ref_beg_seq_id\": 302}, {\"entity_beg_seq_id\": 102, \"length\": 4, \"ref_beg_seq_id\": 318}, {\"entity_beg_seq_id\": 106, \"length\": 2, \"ref_beg_seq_id\": 353}, {\"entity_beg_seq_id\": 108, \"length\": 19, \"ref_beg_seq_id\": 356}, {\"entity_beg_seq_id\": 127, \"length\": 9, \"ref_beg_seq_id\": 379}, {\"entity_beg_seq_id\": 136, \"length\": 25, \"ref_beg_seq_id\": 394}, {\"entity_beg_seq_id\": 161, \"length\": 84, \"ref_beg_seq_id\": 425}, {\"entity_beg_seq_id\": 245, \"length\": 11, \"ref_beg_seq_id\": 510}, {\"entity_beg_seq_id\": 256, \"length\": 2, \"ref_beg_seq_id\": 525}, {\"entity_beg_seq_id\": 258, \"length\": 13, \"ref_beg_seq_id\": 534}, {\"entity_beg_seq_id\": 271, \"length\": 10, \"ref_beg_seq_id\": 549}, {\"entity_beg_seq_id\": 281, \"length\": 17, \"ref_beg_seq_id\": 590}, {\"entity_beg_seq_id\": 298, \"length\": 10, \"ref_beg_seq_id\": 608}, {\"entity_beg_seq_id\": 308, \"length\": 3, \"ref_beg_seq_id\": 619}, {\"entity_beg_seq_id\": 311, \"length\": 1, \"ref_beg_seq_id\": 623}, {\"entity_beg_seq_id\": 312, \"length\": 2, \"ref_beg_seq_id\": 790}, {\"entity_beg_seq_id\": 314, \"length\": 2, \"ref_beg_seq_id\": 793}, {\"entity_beg_seq_id\": 316, \"length\": 25, \"ref_beg_seq_id\": 796}, {\"entity_beg_seq_id\": 341, \"length\": 15, \"ref_beg_seq_id\": 858}, {\"entity_beg_seq_id\": 356, \"length\": 2, \"ref_beg_seq_id\": 877}, {\"entity_beg_seq_id\": 358, \"length\": 3, \"ref_beg_seq_id\": 886}, {\"entity_beg_seq_id\": 361, \"length\": 19, \"ref_beg_seq_id\": 892}, {\"entity_beg_seq_id\": 380, \"length\": 2, \"ref_beg_seq_id\": 914}, {\"entity_beg_seq_id\": 382, \"length\": 31, \"ref_beg_seq_id\": 918}, {\"entity_beg_seq_id\": 413, \"length\": 16, \"ref_beg_seq_id\": 979}, {\"entity_beg_seq_id\": 429, \"length\": 3, \"ref_beg_seq_id\": 996}, {\"entity_beg_seq_id\": 432, \"length\": 25, \"ref_beg_seq_id\": 1003}, {\"entity_beg_seq_id\": 457, \"length\": 4, \"ref_beg_seq_id\": 1035}, {\"entity_beg_seq_id\": 461, \"length\": 26, \"ref_beg_seq_id\": 1043}, {\"entity_beg_seq_id\": 487, \"length\": 20, \"ref_beg_seq_id\": 1082}, {\"entity_beg_seq_id\": 507, \"length\": 24, \"ref_beg_seq_id\": 1152}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"593_90\", \"similarity_cutoff\": 90.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 530, \"ref_beg_seq_id\": 28}]}], \"rcsb_polymer_entity_name_com\": [{\"name\": \"Acylcholine acylhydrolase,Butyrylcholine esterase,Choline esterase II,Pseudocholinesterase\"}], \"rcsb_related_target_references\": [{\"related_resource_name\": \"ChEMBL\", \"related_resource_version\": \"36\", \"related_target_id\": \"CHEMBL2095233\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 529, \"target_beg_seq_id\": 28}]}, {\"related_resource_name\": \"ChEMBL\", \"related_resource_version\": \"36\", \"related_target_id\": \"CHEMBL1914\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 529, \"target_beg_seq_id\": 28}]}, {\"related_resource_name\": \"DrugBank\", \"related_resource_version\": \"5.1\", \"related_target_id\": \"P06276\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 529, \"target_beg_seq_id\": 28}]}, {\"related_resource_name\": \"Pharos\", \"related_resource_version\": \"6.13.4\", \"related_target_id\": \"17341\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 529, \"target_beg_seq_id\": 28}]}], \"rcsb_target_cofactors\": [{\"binding_assay_value\": -4.1, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"QRBVXHWNCSOPKB-KWQFWETISA-N\", \"cofactor_smiles\": \"CN1CC[C@H]2COc3c(O)cccc3[C@H]21\", \"cofactor_resource_id\": \"CHEMBL268481\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"binding_assay_value\": -5.93, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"HDAQKLAKMZNBQB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COc1ccccc1CN(C)CCCCCC(=O)N(C)CCCCCCCCN(C)C(=O)CCCCCN(C)Cc1ccccc1OC\", \"cofactor_name\": \"CAPROCTAMINE\", \"cofactor_resource_id\": \"CHEMBL11805\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"binding_assay_value\": -5.99, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"ZHSORBYPJBKFAV-ZANVPECISA-N\", \"cofactor_smiles\": \"CNC(=O)Oc1ccc2c(c1)[C@@H]1[C@@H](CCN1C)CO2\", \"cofactor_resource_id\": \"CHEMBL11514\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"binding_assay_value\": -6.45, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"MNWULZIBRBDECY-ZANVPECISA-N\", \"cofactor_smiles\": \"CNC(=O)Oc1ccc2c(c1)OC[C@@H]1CCN(C)[C@H]21\", \"cofactor_resource_id\": \"CHEMBL11833\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"binding_assay_value\": -6.53, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"XUQPWMFRKQMTJR-HZMBPMFUSA-O\", \"cofactor_smiles\": \"CNC(=O)Oc1ccc2c(c1)OC[C@@H]1CC[N+](C)(C)[C@H]21\", \"cofactor_resource_id\": \"CHEMBL12324\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"binding_assay_value\": -7.04, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"JNAALEZZYYJZPB-FMWQYVROSA-N\", \"cofactor_smiles\": \"O=C(CCCCCCC(=O)NCCCCCCN1CC[C@H]2COc3ccccc3[C@H]21)NCCCCCCN1CC[C@H]2COc3ccccc3[C@H]21\", \"cofactor_resource_id\": \"CHEMBL2113719\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"binding_assay_value\": -7.11, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"UKFCIGJAJAIROZ-CABZTGNLSA-N\", \"cofactor_smiles\": \"CNC(=O)Oc1cccc2c1OC[C@@H]1CCN(C)[C@H]21\", \"cofactor_resource_id\": \"CHEMBL274107\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"binding_assay_value\": -8.64, \"binding_assay_value_type\": \"pIC50\", \"cofactor_in_ch_ikey\": \"PIJVFDBKTWXHHD-HIFRSBDPSA-N\", \"cofactor_smiles\": \"CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C\", \"cofactor_name\": \"PHYSOSTIGMINE\", \"cofactor_resource_id\": \"CHEMBL94\", \"neighbor_flag\": \"N\", \"resource_name\": \"ChEMBL\", \"resource_version\": \"36\", \"target_resource_id\": \"CHEMBL1914\"}, {\"cofactor_name\": \"Pegvisomant\", \"cofactor_resource_id\": \"DB00082\", \"mechanism_of_action\": \"Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [3948777], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"OEYIOHPDSNJKLS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C[N+](C)(C)CCO\", \"cofactor_chem_comp_id\": \"CHT\", \"cofactor_name\": \"Choline\", \"cofactor_resource_id\": \"DB00122\", \"mechanism_of_action\": \"Choline is a major part of the polar head group of phosphatidylcholine. Phosphatidylcholine's role in the maintenance of cell membrane integrity is vital to all of the basic biological processes: information flow, intracellular communication and bioenergetics. Inadequate choline intake would negatively affect all these processes. Choline is also a major part of another membrane phospholipid, sphingomyelin, also important for the maintenance of cell structure and function. It is noteworthy and not surprising that choline deficiency in cell culture causes apoptosis or programmed cell death. This appears to be due to abnormalities in cell membrane phosphatidylcholine content and an increase in ceramide, a precursor, as well as a metabolite, of sphingomyelin. Ceramide accumulation, which is caused by choline deficiency, appears to activate Caspase, a type of enzyme that mediates apoptosis. Betaine or trimethylglycine is derived from choline via an oxidation reaction. Betaine is one of the factors that maintains low levels of homocysteine by resynthesizing L-methionine from homocysteine. Elevated homocysteine levels are a significant risk factor for atherosclerosis, as well as other cardiovascular and neurological disorders. Acetylcholine is one of the major neurotransmitters and requires choline for its synthesis. Adequate acetylcholine levels in the brain are believed to be protective against certain types of dementia, including Alzheimer's disease.\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [17329059, 16297435, 17636231, 17390078, 16376069], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"HDACQVRGBOVJII-JBDAPHQKSA-N\", \"cofactor_smiles\": \"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC\", \"cofactor_name\": \"Ramipril\", \"cofactor_resource_id\": \"DB00178\", \"mechanism_of_action\": \"Ramipril inhibits the RAAS system by binding to and inhibiting ACE thereby preventing the conversion of angiotensin I to angiotensin II. [T116] As plasma levels of angiotensin II fall, less activation of the G-protein coupled receptors angiotensin receptor I (AT<sub>1</sub>R) and angiotensin receptor II (AT<sub>2</sub>R) occurs. \\r\\n\\r\\nAT<sub>1</sub>R mediates vasoconstriction, inflammation, fibrosis, and oxidative stress through a variety of signaling pathways. [T116] These include G<sub>q</sub> coupling to the inositol triphosphate pathway, activation of phospholipases C, A<sub>2</sub>, and D which contribute to eicosanoid production, activation of Ca<sup>2+</sup>-dependent and MAP kinases, G<sub>i</sub> and G<sub>12/13</sub>, and eventual activation of the Jak/STAT pathway leading to cell growth and production of extracellular matrix components. AT<sub>1</sub>R activation also leads to increased activity of membrane-bound NADH/NADPH oxidase which contributes to production of reactive oxygen species. Decreased activation of this receptor mediates the renoprotective, antihypertensive, and cardioprotective effects of ramipril by reducing inflammation and vasoconstriction.\\r\\n\\r\\nAT<sub>2</sub>R acts in opposition to the effects of AT<sub>1</sub>R by activating phosphotyrosine phosphatases which inhibit MAP kinases, inhibiting Ca<sup>2+</sup> channel opening, and stimulating cGMP and nitric oxide production leading to vasodilation. [T116] These counteracting effects are shared by the Mas receptor which is activated by Ang(1-7), a subtype of angiotensin produced by plasma esterases from AngI or by ACE2 from AngII produced through a secondary pathway by tonin and cathepsin G. Ang(1-7) also activates AT<sub>2</sub>R although the bulk of its effect is mediated by MasR.\\r\\n\\r\\nACE is also responsible for the breakdown of bradykinin. [T116] The resulting buildup of bradykinin due to ACE inhibition is thought to mediate the characteristic dry-cough as a side effect of ACE inhibitor medications.\\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10942157], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"NEYNJQRKHLUJRU-DZUOILHNSA-N\", \"cofactor_smiles\": \"CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O\", \"cofactor_name\": \"Pentagastrin\", \"cofactor_resource_id\": \"DB00183\", \"mechanism_of_action\": \"The exact mechanism by which pentagastrin stimulates gastric acid, pepsin, and intrinsic factor secretion is unknown; however, since pentagastrin is an analogue of natural gastrin, it is believed that it excites the oxyntic cells of the stomach to secrete to their maximum capacity. Pentagastrin stimulates pancreatic secretion, especially when administered in large intramuscular doses. Pentagastrin also increases gastrointestinal motility by a direct effect on the intestinal smooth muscle. However, it delays gastric emptying time probably by stimulation of terminal antral contractions, which enhance retropulsion.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [6873393], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"AXOIZCJOOAYSMI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C\", \"cofactor_chem_comp_id\": \"SCK\", \"cofactor_name\": \"Succinylcholine\", \"cofactor_resource_id\": \"DB00202\", \"mechanism_of_action\": \"Succinylcholine is a depolarizing neuromuscular blocker, meaning it causes a prolonged period of membrane depolarization in order to exert its therapeutic effects. It binds to the post-synaptic cholinergic receptors found on motor endplates, thereby inducing first transient fasciculations followed by skeletal muscle paralysis.[A233250]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26398623], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"XEEQGYMUWCZPDN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F\", \"cofactor_name\": \"Mefloquine\", \"cofactor_resource_id\": \"DB00358\", \"mechanism_of_action\": \"The mechanism of action of mefloquine is not completely understood. Some studies suggest that mefloquine specifically targets the 80S ribosome of the Plasmodium falciparum, inhibiting protein synthesis and causing subsequent schizonticidal effects.[A172000] There are other studies in the literature with limited in vitro data on mefloquine's mechanism of action.[A226938,A15758]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [3878759, 16501066, 16081111], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"YLJREFDVOIBQDA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC1=C2CCCCC2=NC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"THA\", \"cofactor_name\": \"Tacrine\", \"cofactor_resource_id\": \"DB00382\", \"mechanism_of_action\": \"The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine.\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [10375753, 17218977, 12871155, 16860785], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"BGRJTUBHPOOWDU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O\", \"cofactor_name\": \"Sulpiride\", \"cofactor_resource_id\": \"DB00391\", \"mechanism_of_action\": \"Sulpiride is a selective dopamine D2 and D3 receptor antagonist.[A229678,A229683,A229688] _In silico_ studies show that sulpiride may interact with the Asp-119 and Phe-417 amino acid residues of these receptors.[A229688] It is estimated that D2 receptors should be 65-80% occupied for optimal treatment and minimal adverse effects.[A229693]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [3823608, 577162], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"CDOZDBSBBXSXLB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12\", \"cofactor_name\": \"Profenamine\", \"cofactor_resource_id\": \"DB00392\", \"mechanism_of_action\": \"Profenamine's anti-Parkinson action can be attributed to its anticholinergic properties. Profenamine partially blocks central (striatal) cholinergic receptors, thereby helping to balance cholinergic and dopaminergic activity in the basal ganglia; salivation may be decreased, and smooth muscle may be relaxed. Drug-induced extrapyramidal symptoms and those due to parkinsonism may be relieved, but tardive dyskinesia is not alleviated and may be aggravated by anticholinergic effects. Profenamine's local anesthetic effect is due to its antagonism of the NMDA glutamate receptor. Glutamate is recognized as an important transmitter in nociceptive pathways, and the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor, in particular, has been implicated in the mediation of neuropathic pain. Excessive release of glutamate at NMDA receptors on dorsal horn neurons of the spinal cord results in hyperactivation and hypersensitivity of these receptors (perceived as hyperalgesia), thought to be an integral feature of neuropathic pain.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15137175, 21740955], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"OCUJLLGVOUDECM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1\", \"cofactor_name\": \"Dipivefrin\", \"cofactor_resource_id\": \"DB00449\", \"mechanism_of_action\": \"Dipivefrin is a prodrug with little or no pharmacologically activity until it is hydrolyzed into epinephrine inside the human eye. The liberated epinephrine, an adrenergic agonist, appears to exert its action by stimulating \\u03b1 -and/or \\u03b2<sub>2</sub>-adrenergic receptors, leading to a decrease in aqueous production and an enhancement of outflow facility. The dipivefrin prodrug delivery system is a more efficient way of delivering the therapeutic effects of epinephrine, with fewer side effects than are associated with conventional epinephrine therapy.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8446367], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ZPEIMTDSQAKGNT-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2\", \"cofactor_chem_comp_id\": \"Z80\", \"cofactor_name\": \"Chlorpromazine\", \"cofactor_resource_id\": \"DB00477\", \"mechanism_of_action\": \"Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).\\r\\nAdditionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12957233, 12747580, 1654884], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"XSCGXQMFQXDFCW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F\", \"cofactor_name\": \"Triflupromazine\", \"cofactor_resource_id\": \"DB00508\", \"mechanism_of_action\": \"Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT<sub>2B</sub>).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12747580], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"LXZZYRPGZAFOLE-UHFFFAOYSA-L\", \"cofactor_smiles\": \"[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]\", \"cofactor_chem_comp_id\": \"CPT\", \"cofactor_name\": \"Cisplatin\", \"cofactor_resource_id\": \"DB00515\", \"mechanism_of_action\": \"Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20417682], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"PUFQVTATUTYEAL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC\", \"cofactor_name\": \"Cinchocaine\", \"cofactor_resource_id\": \"DB00527\", \"mechanism_of_action\": \"Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel inhibition. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12689511], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"RVOLLAQWKVFTGE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)C(=O)OC1=C[N+](C)=CC=C1\", \"cofactor_name\": \"Pyridostigmine\", \"cofactor_resource_id\": \"DB00545\", \"mechanism_of_action\": \"Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), but also against other targets such as the muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin.[A231004] In the case of AChR antibodies, AChRs are directly bound and cross-linked, impairing acetylcholine binding and contributing through various mechanisms to receptor degradation.[A231004] The lack of acetylcholine signalling leads to muscle tone loss, muscle weakness, and fatigue.[A231004]\\r\\n\\r\\nPyridostigmine is a reversible acetylcholinesterase inhibitor that increases extracellular acetylcholine levels in the neuromuscular junction by impairing its breakdown by acetylcholinesterase.[L32408, L32413] The increased acetylcholine leads to increased neural transmission across the junction, which drastically improves myasthenia gravis symptoms.[A231004]\\r\\n\\r\\nIn addition to its use in myasthenia gravis and in reversing neuromuscular blocks, pyridostigmine is also a common first-line treatment in congenital myasthenic syndromes (CMS), of which there are multiple subtypes caused by mutations in more than 30 distinct genes.[A231009, A231014] CMS present similarly to myasthenia gravis, albeit due to distinct underlying causes, and often benefit from pyridostigmine. However, in some subgroups, treatment with pyridostigmine is detrimental; detailed genetic testing is required before starting therapy.[A231009, A231014]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10942908, 10869589, 8954750], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"SGXXNSQHWDMGGP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O\", \"cofactor_name\": \"Nizatidine\", \"cofactor_resource_id\": \"DB00585\", \"mechanism_of_action\": \"Nizatidine competes with histamine for binding at the H<sub>2</sub>-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8095733], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"GFNANZIMVAIWHM-OBYCQNJPSA-N\", \"cofactor_smiles\": \"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C\", \"cofactor_name\": \"Triamcinolone\", \"cofactor_resource_id\": \"DB00620\", \"mechanism_of_action\": \"Corticosteroids like triamcinolone inhibit phospholipase A2 on cell membranes, preventing the breakdown of lysosomal membranes of leukocytes, which in turn prevent the formation of arachidonic acid, which decrease expression of cyclooxygenase and lipoxygenase, inhibiting synthesis of prostaglandins and leukotrienes.[A184463] Anti-inflammatory activity occurs via reversal of vascular dilation and reducing permeability, which prevents macrophage and leukocyte migration.[A184463] Triamcinolone also inhibits nuclear factor kappa-B, which decreases the production of pro-inflammatory signals such as interleukin-6, interleukin-8, and monocyte chemoattractant protein-1.[A184463]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [3341034], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ASUTZQLVASHGKV-JDFRZJQESA-N\", \"cofactor_smiles\": \"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3\", \"cofactor_chem_comp_id\": \"GNT\", \"cofactor_name\": \"Galantamine\", \"cofactor_resource_id\": \"DB00674\", \"mechanism_of_action\": \"Alzheimer\\u2019s disease is characterized by progressive, irreversible degeneration of acetylcholine-producing neurons, cognitive impairment, and the accumulation of neurofibrillary tangles and amyloid plaques.[A182993,A203558] The cholinergic system plays a critical role in memory, alongside other important neural functions such as attention, learning, stress response, wakefulness and sleep, and sensory information. Studies show that acetylcholine (ACh) is involved in the modulation of acquisition, encoding, consolidation, reconsolidation, extinction, and retrieval of memory. The gradual loss of cholinergic neurons in Alzheimer\\u2019s disease (AD) may, therefore, contribute to the memory loss exhibited by AD patients.[A203558] \\r\\n\\r\\nAcetylcholinesterase is secreted by cholinergic neurons to rapidly hydrolyze ACh at the synaptic cleft to release acetate and choline. Choline is later recycled back into the presynaptic cholinergic neuron via reuptake by the high-affinity choline transporter. There is some evidence demonstrating the potential involvement of the acetylcholinesterase enzyme in the formation of amyloid fibrils.[A203558] Galantamine competitively and reversibly inhibits the anticholinesterase enzyme in the CNS (namely in the frontal cortex and hippocampal regions) [A1022] by binding to the choline-binding site and acyl-binding pocket of the enzyme active site.[A1019] By blocking the breakdown of ACh, galantamine enhances ACh levels in the synaptic cleft.[A203558] \\r\\n\\r\\nNicotinic acetylcholine receptors (nAChR) in the CNS are mostly expressed at the presynaptic neuronal membrane to control the release of multiple neurotransmitters, such as ACh, glutamate, GABA, dopamine, serotonin, norepinephrine.[A182993,A203558] Agonists of nAChRs improve performance in cognitive tasks, while antagonists of nAChR impair cognitive processes.[A203558] Some studies show a decrease in the expression and activity of nAChRs in patients with AD, which may explain the reduction in central cholinergic neurotransmission in these patients.[A1022] Galantamine binds to nAChRs at the allosteric site,[A182993,A203591] leading to a conformational change of the receptor, increased ACh release, and increased activity of neighbouring glutaminergic and serotoninergic neurons.[A182993] The modulation of nAChRs facilitates both excitatory and inhibitory cholinergic transmissions in brain tissues and increases receptor sensitivity. The modulated release of other neurotransmitters by galantamine may also contribute to the upregulation of nAChRs and amelioration of behavioural symptoms in AD.[A182993]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17159811, 11888344, 19811027, 12177686], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"MUCZHBLJLSDCSD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)OP(F)(=O)OC(C)C\", \"cofactor_name\": \"Isoflurophate\", \"cofactor_resource_id\": \"DB00677\", \"mechanism_of_action\": \"The mechanism of isoflurophate's action involves the irreversible inhibition of cholinesterase.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11405252, 12459190, 1511344, 1776688, 2361169], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"RCKMWOKWVGPNJF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)C(=O)N1CCN(C)CC1\", \"cofactor_name\": \"Diethylcarbamazine\", \"cofactor_resource_id\": \"DB00711\", \"mechanism_of_action\": \"The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against <i>Brugia malayi</i> microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action <i>in vivo</i> and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [2609206], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"MFDFERRIHVXMIY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1\", \"cofactor_name\": \"Procaine\", \"cofactor_resource_id\": \"DB00721\", \"mechanism_of_action\": \"Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [3675616, 3022829, 18450526], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"JBKPUQTUERUYQE-UHFFFAOYSA-O\", \"cofactor_smiles\": \"C[N+]1=C(\\\\C=N\\\\O)C=CC=C1\", \"cofactor_name\": \"Pralidoxime\", \"cofactor_resource_id\": \"DB00733\", \"mechanism_of_action\": \"Pralidoxime is an antidote to organophosphate pesticides and chemicals. Organophosphates bind to the esteratic site of acetylcholinesterase, which results initially in reversible inactivation of the enzyme. Acetylcholinesterase inhibition causes acetylcholine to accumulate in synapses, producing continuous stimulation of cholinergic fibers throughout the nervous systems. If given within 24 hours after organophosphate exposure, pralidoxime reactivates the acetylcholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18825528, 11393267], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"JXSJBGJIGXNWCI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC\", \"cofactor_name\": \"Malathion\", \"cofactor_resource_id\": \"DB00772\", \"mechanism_of_action\": \"Malathion is a nonsystemic, wide-spectrum organophosphate insecticide. It inhibits acetylcholinesterase activity of most eukaryotes. Malathion is toxic to aquatic organisms, but has a relatively low toxicity for birds and mammals. The major metabolites of malathion are mono- and di-carboxylic acid derivatives, and malaoxon is a minor metabolite. However, it is malaoxon that is the strongest cholinesterase inhibitor. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. Because of its essential function, chemicals that interfere with the action of cholinesterase are potent neurotoxins, causing muscle spasms and ultimately death.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16782587, 17364237, 16716398, 10592235], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"IPVQLZZIHOAWMC-QXKUPLGCSA-N\", \"cofactor_smiles\": \"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O\", \"cofactor_name\": \"Perindopril\", \"cofactor_resource_id\": \"DB00790\", \"mechanism_of_action\": \"There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Perindoprilat, the active metabolite of perindopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Perindopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20555429], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ADEBPBSSDYVVLD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1\", \"cofactor_name\": \"Donepezil\", \"cofactor_resource_id\": \"DB00843\", \"mechanism_of_action\": \"\\r\\nThe commonly accepted cholinergic hypothesis[A182369] proposes that a portion of the cognitive and behavioral decline associated with Alzheimer's are the result of decreased cholinergic transmission in the central nervous system. Donepezil selectively and reversibly inhibits the acetylcholinesterase enzyme, which normally breaks down acetylcholine. The main pharmacological actions of this drug are believed to occur as the result of this enzyme inhibition, enhancing cholinergic transmission, which relieves the symptoms of Alzheimer's dementia. In addition to the above, other mechanisms of action of donepezil are possible, including the opposition of glutamate-induced excitatory transmission via downregulation of NMDA receptors and the regulation of amyloid proteins, which have demonstrated significant effects on the disease process of Alzheimer's.[A182333,A182351,A182444] Other possible targets for donepezil may also include the inhibition various inflammatory signaling pathways, exerting neuroprotective effects.[A182339,A182393]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16863459, 14751402, 23930233, 11256231], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"MXOAEAUPQDYUQM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OCC(O)COC1=CC=C(Cl)C=C1\", \"cofactor_name\": \"Chlorphenesin\", \"cofactor_resource_id\": \"DB00856\", \"mechanism_of_action\": \"The mechanism of action of chlorphenesin is not well defined, and its effects are measured mainly by subjective responses. It is known that chlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [466732], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"MAFMQEKGGFWBAB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC\", \"cofactor_name\": \"Benzonatate\", \"cofactor_resource_id\": \"DB00868\", \"mechanism_of_action\": \"Benzonatate is a local anesthetic drug that acts peripherally by anesthetizing and reducing the activity of vagal stretch receptors or nerve fibres located in the respiratory passages, lungs, and pleura.[A189519,L11193] Once the stretch receptors are stimulated, they send impulses to the cough centre located in the medulla via an afferent pathway consisting of sensory nerve fibres or the vagus nerve. The efferent signal is then generated that sends impulses to the expiratory muscles to produce a cough.[A190270] Anesthetizing these receptors by benzonatate results in the inhibition of the cough reflex activity and cough production.[A189519,L11193] Benzonatate also inhibits the transmission of impulses of the cough reflex in the vagal nuclei of the medulla.[A190267] There are several proposed mechanisms of benzonatate; it is also a potent voltage-gated sodium channel inhibitor.[A189519]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [28334901], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"XWTYSIMOBUGWOL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1\", \"cofactor_name\": \"Terbutaline\", \"cofactor_resource_id\": \"DB00871\", \"mechanism_of_action\": \"Terbutaline is a selective beta-2 adrenergic receptor agonist.[A230328] Agonism of these receptors in bronchioles activates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP).[A230338] Increased cAMP decreases intracellular calcium, activating protein kinase A, inactivating myosin light-chain kinase, activating myosin light-chain phosphatase, and finally relaxing smooth muscle in the bronchiole.[A230338]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15449725, 10446376], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"HAWPXGHAZFHHAD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(CCCl)CCCl\", \"cofactor_name\": \"Mechlorethamine\", \"cofactor_resource_id\": \"DB00888\", \"mechanism_of_action\": \"Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Mechlorethamine is cell cycle phase-nonspecific.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"CMHHMUWAYWTMGS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCOC1=CC(=CC=C1N)C(=O)OCCN(CC)CC\", \"cofactor_name\": \"Oxybuprocaine\", \"cofactor_resource_id\": \"DB00892\", \"mechanism_of_action\": \"Oxybuprocaine binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [4069587, 6621359], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ZPUCINDJVBIVPJ-LJISPDSOSA-N\", \"cofactor_smiles\": \"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C\", \"cofactor_chem_comp_id\": \"COC\", \"cofactor_name\": \"Cocaine\", \"cofactor_resource_id\": \"DB00907\", \"mechanism_of_action\": \"Cocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Its effect on dopamine levels is most responsible for the addictive property of cocaine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27392137, 8632517], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"HDZAQYPYABGTCL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2\", \"cofactor_name\": \"Hexafluronium\", \"cofactor_resource_id\": \"DB00941\", \"mechanism_of_action\": \"Hexafluronium bromide is a non-competitive reversible inhibitor of human plasma cholinesterase or pseudocholinesterase.\\r\\nHexafluornium probably binds to anionic side receptors near the active center, causing a conformational change in the enzyme, preventing acylation of the esteratic site. The esteratic site on cholistereases is where acetylcholine is hydrolyzed to acetic acid and choline. \\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [948350, 11752352, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"RWZVPVOZTJJMNU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C\", \"cofactor_name\": \"Demecarium\", \"cofactor_resource_id\": \"DB00944\", \"mechanism_of_action\": \"Demecarium is an indirect-acting parasympathomimetic agent, also known as a cholinesterase inhibitor and anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle (affecting the accommodation reflex and causing a spasm of the focus to near vision). The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure. Of the two actions, the effect on the accommodation reflex is the more transient and generally disappears before termination of the miosis.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7196602, 8430939], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"SKYSRIRYMSLOIN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1\", \"cofactor_name\": \"Cyclopentolate\", \"cofactor_resource_id\": \"DB00979\", \"mechanism_of_action\": \"By blocking muscarinic receptors, cyclopentolate produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15121994], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"XSVMFMHYUFZWBK-NSHDSACASA-N\", \"cofactor_smiles\": \"CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C\", \"cofactor_name\": \"Rivastigmine\", \"cofactor_resource_id\": \"DB00989\", \"mechanism_of_action\": \"Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11752352, 11078030, 11139819, 19370562, 16437532, 19470293, 19420308, 19374459, 18671661, 18044073, 14587496, 12636181, 34269114], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"VWLHWLSRQJQWRG-UHFFFAOYSA-O\", \"cofactor_smiles\": \"CC[N+](C)(C)C1=CC(O)=CC=C1\", \"cofactor_chem_comp_id\": \"EDR\", \"cofactor_name\": \"Edrophonium\", \"cofactor_resource_id\": \"DB01010\", \"mechanism_of_action\": \"Edrophonium works by prolonging the action acetylcholine, which is found naturally in the body. It does this by inhibiting the action of the enzyme acetylcholinesterase. Acetylcholine stimulates nicotinic and muscarinic receptors. When stimulated, these receptors have a range of effects.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [1438284, 9398183], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"REQCZEXYDRLIBE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCNC(=O)C1=CC=C(N)C=C1\", \"cofactor_name\": \"Procainamide\", \"cofactor_resource_id\": \"DB01035\", \"mechanism_of_action\": \"Procainamide is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10192412, 3982389], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"BJOLKYGKSZKIGU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOP(=O)(OCC)SCC[N+](C)(C)C\", \"cofactor_name\": \"Echothiophate\", \"cofactor_resource_id\": \"DB01057\", \"mechanism_of_action\": \"Echothiophate Iodide is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. Echothiophate iodide binds irreversibly to cholinesterase, and is long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [2481033, 11752352], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"JWZZKOKVBUJMES-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)C1=CC(O)=C(O)C=C1\", \"cofactor_name\": \"Isoprenaline\", \"cofactor_resource_id\": \"DB01064\", \"mechanism_of_action\": \"Isoprenaline is a non-selective beta adrenergic receptor agonist.[A15638] Agonism of beta-1 and beta-2 adrenergic receptors causes the alpha subunit of G-protein coupled receptors to exchange GMP for GTP, activating them, and allowing the alpha subunit to dissociate from the beta and gamma subunits.[A233584,A233644] Dissociation of the alpha subunit activates adenylate cyclase, converting ATP to cyclic AMP.[A233584] Cyclic AMP activates protein kinase A (PKA), which phosphorylates cardiac L-type calcium channels such as Ca<sub>v</sub>1.2.[A233584,A233629,A233644] These channels depolarize cells by inward active transport of calcium ions.[A233629,A233644]\\r\\n\\r\\nAgonism of beta-1 adrenergic receptors lead to increased strength of contractility, conduction of nerve impulses, speed of relaxation, and rate in the heart.[A233584] \\r\\n\\r\\nAgonism of beta-2 adrenergic receptors leads to glycogenolysis in the liver,[A233649] glucagon release from the pancreas, and activation of the renin-angiotensin-aldosterone system.[A233584]\\r\\n\\r\\nIn the alveoli, agonism of beta-2 adrenergic receptors, activates similar pathways to the heart, however the end result is regulation of sodium channels, the cystic fibrosis transmembrane conductance regulator (CFTR), and sodium potassium ATPase.[A233714] PKA phosphorylates scaffolding proteins and sodium channels, increasing the number of sodium channels on the apical side of alveolar cells and increasing active transport of sodium ions into cells.[A233714] Agonism of beta-2 adrenergic receptors can also increase chloride ion transport across CFTR.[A233714] Together, these actions lead to passive transport of water out of the alveoli, and the clearance of alveolar fluid.[A233714]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22817559], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"CHQOEHPMXSHGCL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1\", \"cofactor_name\": \"Trimethaphan\", \"cofactor_resource_id\": \"DB01116\", \"mechanism_of_action\": \"Trimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. Trimethaphan's hypotensive effect is due to reduction in sympathetic tone and vasodilation, and is primarily postural.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7457791], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"OMHBPUNFVFNHJK-UHFFFAOYSA-P\", \"cofactor_smiles\": \"CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl\", \"cofactor_name\": \"Ambenonium\", \"cofactor_resource_id\": \"DB01122\", \"mechanism_of_action\": \"Ambenonium exerts its actions against myasthenia gravis by competitive, reversible inhibition of acetylcholinesterase. The disease myasthenia gravis occurs when the body inappropriately produces antibodies against acetylcholine receptors, and thus inhibits proper acetylcholine signal transmission (when acetylcholine binds to acetylcholine receptors of striated muscle fibers, it stimulates those fibers to contract). Ambenonium reversibly binds acetylcholinesterase at the anionic site, which results in the blockage of the site of acetycholine binding, thereby inhibiting acetylcholine hydrolysis and enhancing cholinergic function through the accumulation of acetycholine at cholinergic synpases. Elevated acetylcholine levels lead to facilitates transmission of impulses across the myoneural junction. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [1801966], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"GBLRQXKSCRCLBZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC\", \"cofactor_name\": \"Doxacurium\", \"cofactor_resource_id\": \"DB01135\", \"mechanism_of_action\": \"Doxacurium chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission (non-depolarizing). This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [2972233, 2145783], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"VDANGULDQQJODZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1\", \"cofactor_name\": \"Chloroprocaine\", \"cofactor_resource_id\": \"DB01161\", \"mechanism_of_action\": \"Chloroprocaine acts mainly by binding to the alpha subunit on the cytoplasmic region of voltage-gated sodium channels and inhibiting sodium influx in neuronal cell membranes.[L43402] This lowers the nerve membrane permeability to sodium and decreases the rate of rise of the action potential.[L43377,L43382] Therefore, chloroprocaine inhibits signal conduction and leads to a reversible nerve conduction blockade.[L43402] The progression of anesthesia depends on the diameter, myelination and conduction velocity of nerve fibers, and the order of loss of nerve function is the following: 1) pain, 2) temperature, 3) touch, 4) proprioception, and 5) skeletal muscle tone.[L43377,L43382]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7081736, 385208, 11305839, 3111302, 7425357], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"JFJZZMVDLULRGK-URLMMPGGSA-O\", \"cofactor_smiles\": \"[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3\", \"cofactor_name\": \"Tubocurarine\", \"cofactor_resource_id\": \"DB01199\", \"mechanism_of_action\": \"Tubocurarine exerts its neuromuscular blocking effects via inhibition of acetylcholine (ACh) activity.[A216008] It exerts a sort of reversible competitive antagonistic effect at post-synaptic nicotinic receptors, reducing the probability of activation via ACh by repeatedly associating and dissociating from these receptors - in doing so, tubocurarine prevents depolarization of the affected nerves. This mechanism distinguishes tubocurarine and similars from other neuromuscular blocking agents and is the reason they are referred to as \\\"non-depolarizing neuromuscular blockers\\\".[A216008]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"YQEZLKZALYSWHR-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNC1(CCCCC1=O)C1=CC=CC=C1Cl\", \"cofactor_name\": \"Ketamine\", \"cofactor_resource_id\": \"DB01221\", \"mechanism_of_action\": \"Ketamine interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.[A2187]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9806706], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ILVYCEVXHALBSC-OTBYEXOQSA-N\", \"cofactor_smiles\": \"COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\\\\C=C\\\\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC\", \"cofactor_name\": \"Mivacurium\", \"cofactor_resource_id\": \"DB01226\", \"mechanism_of_action\": \"Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8922768], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"MTCUAOILFDZKCO-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C\", \"cofactor_chem_comp_id\": \"DME\", \"cofactor_name\": \"Decamethonium\", \"cofactor_resource_id\": \"DB01245\", \"mechanism_of_action\": \"Binds to the nicotinic acetycholine receptors (by virtue of its similarity to acetylcholine) in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrance remains depolarized and unresponsive to any other impulse, causing muscle paralysis.\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [3801037, 5598433], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"GVEAYVLWDAFXET-XGHATYIMSA-N\", \"cofactor_smiles\": \"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1\", \"cofactor_name\": \"Pancuronium\", \"cofactor_resource_id\": \"DB01337\", \"mechanism_of_action\": \"Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [1191483], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"OWWLUIWOFHMHOQ-XGHATYIMSA-N\", \"cofactor_smiles\": \"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1\", \"cofactor_name\": \"Pipecuronium\", \"cofactor_resource_id\": \"DB01338\", \"mechanism_of_action\": \"Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [6248079], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"KWGRBVOPPLSCSI-WPRPVWTQSA-N\", \"cofactor_smiles\": \"CN[C@@H](C)[C@H](O)C1=CC=CC=C1\", \"cofactor_name\": \"Ephedrine\", \"cofactor_resource_id\": \"DB01364\", \"mechanism_of_action\": \"Ephedrine is a direct and indirect sympathomimetic amine.[A193650] As a direct effect, ephedrine activates alpha-adrenergic and beta-adrenergic receptors. As an indirect effect, it inhibits norepinephrine reuptake and increases the release of norepinephrine from vesicles in nerve cells.[A193650] These actions combined lead to larger quantities of norepinephrine present in the synapse for more extended periods of time, increasing stimulation of the sympathetic nervous system.[A193650]\\r\\n\\r\\nEphedrine acts as an agonist of alpha-1, beta-1 and beta-2-adrenergic receptors. The stimulation of alpha-1-adrenergic receptors causes the constriction of veins and a rise in blood pressure, the stimulation of beta-1-adrenergic receptors increases cardiac chronotropy and inotropy, and the stimulation of beta-2-adrenergic receptors causes vasodilation and bronchodilation.[A193650]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [698301], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ALWKGYPQUAPLQC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C\", \"cofactor_name\": \"Neostigmine\", \"cofactor_resource_id\": \"DB01400\", \"mechanism_of_action\": \"Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9697967], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ANZXOIAKUNOVQU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C\", \"cofactor_name\": \"Bambuterol\", \"cofactor_resource_id\": \"DB01408\", \"mechanism_of_action\": \"The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [34269114, 1994894, 27744187, 8905251, 10839906], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"MJUJXFBTEFXVKU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"[H]P(=O)(OCC)OCC\", \"cofactor_chem_comp_id\": \"DEP\", \"cofactor_name\": \"Diethyl phosphonate\", \"cofactor_resource_id\": \"DB02811\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"BCDIWLCKOCHCIH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CP(O)=O\", \"cofactor_name\": \"Methylphosphinic Acid\", \"cofactor_resource_id\": \"DB02845\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"OIPILFWXSMYKGL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(=O)OCC[N+](C)(C)C\", \"cofactor_chem_comp_id\": \"ACH\", \"cofactor_name\": \"Acetylcholine\", \"cofactor_resource_id\": \"DB03128\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [34269114], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"FERIUCNNQQJTOY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC(O)=O\", \"cofactor_chem_comp_id\": \"BUA\", \"cofactor_name\": \"Butyric Acid\", \"cofactor_resource_id\": \"DB03568\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"JYJAEHAURXXPSD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C(NC1=C2C=CC=CC2=NC2=C1CCCC2)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"760\", \"cofactor_name\": \"9-N-Phenylmethylamino-Tacrine\", \"cofactor_resource_id\": \"DB03672\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10592235, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"SXGZJKUKBWWHRA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OS(=O)(=O)CCN1CCOCC1\", \"cofactor_chem_comp_id\": \"MES\", \"cofactor_name\": \"2-(N-morpholino)ethanesulfonic acid\", \"cofactor_resource_id\": \"DB03814\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ZJXZSIYSNXKHEA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOP(O)(O)=O\", \"cofactor_chem_comp_id\": \"EFS\", \"cofactor_name\": \"Ethyl dihydrogen phosphate\", \"cofactor_resource_id\": \"DB03822\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"QPPQHRDVPBTVEV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)OP(O)(O)=O\", \"cofactor_chem_comp_id\": \"ISP\", \"cofactor_name\": \"Phosphorylisopropane\", \"cofactor_resource_id\": \"DB03976\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [10592235], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"AWBGQVBMGBZGLS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC(=O)SCC[N+](C)(C)C\", \"cofactor_chem_comp_id\": \"BCH\", \"cofactor_name\": \"Butyrylthiocholine\", \"cofactor_resource_id\": \"DB04250\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [16837465, 10592235], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"FOCVUCIESVLUNU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"S=P(N1CC1)(N1CC1)N1CC1\", \"cofactor_name\": \"Thiotepa\", \"cofactor_resource_id\": \"DB04572\", \"mechanism_of_action\": \"The alkyl group is attached to the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring. They stop tumor growth by crosslinking guanine nucleobases in DNA double-helix strands, directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. These drugs act nonspecifically.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"PBHFNBQPZCRWQP-QUCCMNQESA-N\", \"cofactor_smiles\": \"[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC3=CC=CC=C3)=C1)N2C\", \"cofactor_name\": \"Phenserine\", \"cofactor_resource_id\": \"DB04892\", \"mechanism_of_action\": \"Phenserine is a highly selective, reversible acetylcholinesterase inhibitor, a mechanism of action known to improve memory and cognition in Alzheimer\\u2019s subjects. Phenserine may prove to concentrate in the brain rapidly which would reduce the incidence of drug toxicity and side effects.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15620572, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"KPBZROQVTHLCDU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC\", \"cofactor_name\": \"Clevidipine\", \"cofactor_resource_id\": \"DB04920\", \"mechanism_of_action\": \"Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10072476], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_name\": \"Regramostim\", \"cofactor_resource_id\": \"DB05386\", \"mechanism_of_action\": \"This drug activates mononuclear phagocytes, promotes migration of epithelial cells, and further regulates cytokine production. In 2 recent placebo-controlled studies involving venous leg ulceration, subcutaneous perilesional injections of recombinant human granulocyte-macrophage colony-stimulating factor were found to be significantly better than placebo in the time to complete wound healing. In other studies, recombinant human granulocyte-macrophage colony-stimulating factor was administered topically to wounds. Several case reports have also demonstrated the use of recombinant human granulocyte-macrophage colony-stimulating factor for postsurgical wounds, chronic leg ulcers of sickle cell anemia patients, and refract and refractory pyoderma gangrenosum. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [1996559], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"OUPXSLGGCPUZJJ-SARDKLJWSA-N\", \"cofactor_smiles\": \"CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O\", \"cofactor_name\": \"Sar9, Met (O2)11-Substance P\", \"cofactor_resource_id\": \"DB05875\", \"mechanism_of_action\": \"The endogenous receptor for Substance P is neurokinin 1 receptor (NK1-receptor, NK1R). Substance P has been shown to stimulate cellular growth in cell culture [2], and it was shown that Substance P could promote wound healing of non-healing ulcers in humans. [3] It has also been shown to reverse diabetes in mice.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [6177830], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"RSWOJTICKMKTER-QXLBVTBOSA-N\", \"cofactor_smiles\": \"[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1\", \"cofactor_name\": \"Isavuconazonium\", \"cofactor_resource_id\": \"DB06636\", \"mechanism_of_action\": \"Isavuconazonium sulfate is the prodrug of isavuconazole, an azole antifungal. Isavuconazole inhibits the synthesis of ergosterol, a key component of the fungal cell membrane, by inhibiting cytochrome P-450-dependent enzyme lanosterol 14-alpha-demethylase (Erg11p). This enzyme is responsible for the conversion of lanosterol to ergosterol. An accumulation of methylated sterol precursors and a depletion of ergosterol within the fungal cell membrane weaken the membrane structure and function. Mammalian cell demethylation is less sensitive to isavuconazole inhibition.[L49211] \\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_name\": \"Aprotinin\", \"cofactor_resource_id\": \"DB06692\", \"mechanism_of_action\": \"Aprotinin inhibits serine proteases including trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/mL, and kallikrein at 300,000 IU/mL. The inhibition of kallikrein inhibits formation of factor XIIa. This inhibits the intrinsic pathway of coagulation and fibrinolysis. Inhibition of plasmin also slows fibrinolysis.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"KWIUHFFTVRNATP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C[N+](C)(C)CC([O-])=O\", \"cofactor_name\": \"Betaine\", \"cofactor_resource_id\": \"DB06756\", \"mechanism_of_action\": \"Homocystinuria is a hereditary disorder characterized by high levels of the amino acid homocysteine. This condition can be caused by deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl).[L43105] CBS converts homocysteine to cystathionine, and a deficiency in this enzyme can lead to an accumulation of homocysteine. MTHFR is responsible for producing 5-methyltetrahydrofolate, a methyl donor that participates in the conversion of homocysteine back to methionine; therefore, an MTHFR deficiency can also lead to homocystinuria.[A252240] Additionally, a defect in cobalamin (vitamin B12) cofactor metabolism can lead to homocystinuria, since a metabolite of cobalamin (methylcobalamin) promotes the conversion of homocysteine to methionine.[A252235] \\r\\n\\r\\nBetaine transfers a methyl group via the enzyme betaine homocysteine methyl transferase (BHMT), converting homocysteine back into methionine and dimethylglycine (DMG).[A252240,L43110] In patients with homocystinuria, betaine reduces homocysteine levels and improves health outcomes.[A252235]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9229847, 6406829], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"YKPUWZUDDOIDPM-SOFGYWHQSA-N\", \"cofactor_smiles\": \"COC1=C(O)C=CC(CNC(=O)CCCC\\\\C=C\\\\C(C)C)=C1\", \"cofactor_chem_comp_id\": \"4DY\", \"cofactor_name\": \"Capsaicin\", \"cofactor_resource_id\": \"DB06774\", \"mechanism_of_action\": \"Capsaicin has been shown to reduce the amount of substance P associated with inflammation - however this is not believed to be its main mechanism in the relief of pain [A32319]. Capsaicin's mechanism of action is attributed to \\\"defunctionalization\\\" of nociceptor fibers by inducing a topical hypersensitivity reaction on the skin. This alteration in pain mechanisms is due to many of the following: temporary loss of membrane potential, inability to transport neurotrophic factors leading to altered phenotype, and reversible retraction of epidermal and dermal nerve fiber terminals. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18069241], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"LDMOEFOXLIZJOW-UHFFFAOYSA-M\", \"cofactor_smiles\": \"CCCCCCCCCCCCS([O-])(=O)=O\", \"cofactor_chem_comp_id\": \"DSC\", \"cofactor_name\": \"DODECANESULFONATE ION\", \"cofactor_resource_id\": \"DB07681\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10592235, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ZUCWQTWGZGIYPV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"IC1=CC=CC(CNC2=C3CCCCC3=NC3=C2C=CC=C3)=C1\", \"cofactor_chem_comp_id\": \"I40\", \"cofactor_name\": \"9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE\", \"cofactor_resource_id\": \"DB07940\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10592235, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"WAVIZOVSJOXCKT-OWCLPIDISA-N\", \"cofactor_smiles\": \"CCCCCCP(O)(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C\", \"cofactor_chem_comp_id\": \"MPA\", \"cofactor_name\": \"(1R)-menthyl hexyl phosphonate group\", \"cofactor_resource_id\": \"DB08200\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10592235, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"WAVIZOVSJOXCKT-XHSDSOJGSA-N\", \"cofactor_smiles\": \"CCCCCCP(O)(=O)O[C@H]1C[C@@H](C)CC[C@@H]1C(C)C\", \"cofactor_chem_comp_id\": \"MPC\", \"cofactor_name\": \"(1S)-menthyl hexyl phosphonate group\", \"cofactor_resource_id\": \"DB08201\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10592235, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"DUNFIZRDIMDMIH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCO[P@](O)(=O)N(CC)CC\", \"cofactor_chem_comp_id\": \"TUN\", \"cofactor_name\": \"Ethyl hydrogen diethylamidophosphate\", \"cofactor_resource_id\": \"DB08658\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [10592235, 37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"PBAPPPCECJKMCM-IBGZPJMESA-N\", \"cofactor_smiles\": \"NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1\", \"cofactor_chem_comp_id\": \"H6U\", \"cofactor_name\": \"Mirabegron\", \"cofactor_resource_id\": \"DB08893\", \"mechanism_of_action\": \"Mirabegron is a potent and selective agonist of beta-3 adrenergic receptors. The activation of beta-3 receptors relaxes detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, which increases the bladder's storage capacity thereby alleviating feelings of urgency and frequency.[L32853]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22509825], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"ASMXXROZKSBQIH-VITNCHFBSA-N\", \"cofactor_smiles\": \"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1\", \"cofactor_name\": \"Aclidinium\", \"cofactor_resource_id\": \"DB08897\", \"mechanism_of_action\": \"Aclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23566013, 20332199], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"VRYMTAVOXVTQEF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1\", \"cofactor_name\": \"Moxisylyte\", \"cofactor_resource_id\": \"DB09205\", \"mechanism_of_action\": \"Moxisylyte is vasodilator that works as a specific alpha-adrenergic blocking agent. Its action is known to be competitive against norepinephrine without beta-receptor blocking, anti-angiotensin or anti-serotonin activity.[A31640]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8866639], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"QTGAJCQTLIRCFL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1\", \"cofactor_name\": \"Propacetamol\", \"cofactor_resource_id\": \"DB09288\", \"mechanism_of_action\": \"As propacetamol is a prodrug, its mechanism of action is directly linked to the activity of paracetamol. The mechanism of action of paracetamol is described by the inhibition of prostaglandin synthesis.[L1511] This inhibition is attained by inhibition of COX-1 and COX-2 in an environment where arachidonic acid and peroxides are kept low.[L1519] It is considered that paracetamol presents a very complex mechanism of action involving effects in the peripheral system, described by direct COX inhibition; the central system, characterized by inhibition of COX, serotonergic descending neuronal pathway, L-arginine/NO pathway and cannabinoid system; and a redox mechanism.[A32056] In the brain and spinal cord, paracetamol can combine with arachidonic acid to form N-arachidonoylphenolamine. This metabolite is an activator of capsaicin receptor (TRPV1) and cannabinoid CB1.[L1519]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [14711849], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"IUWVALYLNVXWKX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCOC(=O)C1=CC=C(N)C=C1\", \"cofactor_name\": \"Butamben\", \"cofactor_resource_id\": \"DB11148\", \"mechanism_of_action\": \"Butamben acts by inhibiting the voltage-gated calcium channels in dorsal root ganglion neurons.[A32662] The modification in this channels is thought to cause a disturbance of the channel kinetics acceleration.[A27147] It is reported as well that butamben is an inhibitor of the sodium channels and a delayed rectifier of potassium currents. All the effects of butamben are performed in the root ganglion neurons which suggests that the related anesthetic effect may be caused by the reduced electrical excitability.[A32663]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"OEBRKCOSUFCWJD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COP(=O)(OC)OC=C(Cl)Cl\", \"cofactor_name\": \"Dichlorvos\", \"cofactor_resource_id\": \"DB11397\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20229498], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"JLICHNCFTLFZJN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1\", \"cofactor_name\": \"Meptazinol\", \"cofactor_resource_id\": \"DB13478\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"UDKCHVLMFQVBAA-UHFFFAOYSA-M\", \"cofactor_smiles\": \"C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O\", \"cofactor_name\": \"Choline salicylate\", \"cofactor_resource_id\": \"DB14006\", \"mechanism_of_action\": \"Choline salicylate relieves pain by inhibition of prostaglandin synthesis and reduces fever by acting on the hypothalamus heat-regulating center. It also inhibits the generation of impulses through the inhibition of cyclooxygenase enzyme (COX) [L2132], [A245119].  \\r\\n\\r\\nCyclooxygenase is involved in the production of prostaglandins, in response to injury and after various other stimuli. The prostaglandins promote pain, swelling, and inflammation. The choline salicylate decreases inflammation and pain by reducing the production of these prostaglandins in the area of the mouth it is applied to [L2137].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17329059, 16297435, 17636231, 17390078, 16376069], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"IUCJMVBFZDHPDX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C1CN1C1=NC(=NC(=N1)N1CC1)N1CC1\", \"cofactor_name\": \"Tretamine\", \"cofactor_resource_id\": \"DB14031\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"cofactor_in_ch_ikey\": \"JKVNJTYHRABHIY-WXVUKLJWSA-N\", \"cofactor_smiles\": \"[H][C@]12C[C@@H](OC(=O)C3=CC=CC=C3)C=C[C@]11CCN(C)CC3=CC=C(OC)C(O2)=C13\", \"cofactor_name\": \"Benzgalantamine\", \"cofactor_resource_id\": \"DB19353\", \"mechanism_of_action\": \"[Galantamine], the active moiety of benzgalantamine, is a reversible and competitive inhibitor of acetylcholinesterase.[L51534] It inhibits the hydrolysis of acetylcholine by acetylcholinesterase, thereby increasing the concentration of available acetylcholine. \\r\\n\\r\\nAlthough the underlying etiology of Alzheimer's disease is largely unclear, it appears that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease and that the degree of this degeneration correlates with the degree of cognitive impairment and density of amyloid plaques.[L51534] By increasing the concentration of available acetylcholine, galantamine may enhance cholinergic function and improve dementia symptoms.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17159811, 11888344, 19811027, 12177686], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P06276\"}, {\"binding_assay_value\": 10.95, \"binding_assay_value_type\": \"pKi\", \"cofactor_smiles\": \"CN(C)CCN(CC1CCCN(C2Cc3ccccc3C2)C1)C(=O)c1ccc2ccccc2c1.Cl\", \"cofactor_resource_id\": \"CHEMBL4080419\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29227101], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 10.67, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"Cl.O=C(NCCCNc1c2c(nc3ccccc13)CCCC2)c1ccc(F)cc1\", \"cofactor_resource_id\": \"CHEMBL1814730\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21570751], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 10.52, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"CN(CCCNC(=O)CCc1c[nH]c2ccccc12)CCCNc1c2c(nc3ccccc13)CCCC2\", \"cofactor_resource_id\": \"CHEMBL224336\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16279781], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 10.45, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"Cl.O=C(NCCCCNc1c2c(nc3ccccc13)CCCC2)c1ccc(F)cc1\", \"cofactor_resource_id\": \"CHEMBL1814731\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21570751], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 10.42, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"COc1ccc2oc(C(=O)NCCCCCCCCCCNc3c4c(nc5ccccc35)CCCC4)cc(=O)c2c1.Cl\", \"cofactor_resource_id\": \"CHEMBL2019034\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22243648], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 10.35, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"Cl.O=C(NCCNc1c2c(nc3ccccc13)CCCC2)c1ccc(F)cc1\", \"cofactor_resource_id\": \"CHEMBL1814729\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21570751], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 10.22, \"binding_assay_value_type\": \"pKi\", \"cofactor_smiles\": \"O=[N+]([O-])c1cccc2c(NCCCCCCCCNc3c4c(nc5ccccc35)CCCC4)c3c(nc12)CCCC3\", \"cofactor_resource_id\": \"CHEMBL3099496\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24900626], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 10.15, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"O=C(c1cccc2ccccc12)n1nc(OCCCN2CCCCC2)c2ccccc21\", \"cofactor_resource_id\": \"CHEMBL4444855\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [30685536], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}, {\"binding_assay_value\": 8.57, \"binding_assay_value_type\": \"pKi\", \"cofactor_smiles\": \"COCCN(C[C@@H]1CCCN(C2Cc3ccccc3C2)C1)C(=O)c1ccc2ccccc2c1\", \"cofactor_chem_comp_id\": \"3F9\", \"cofactor_resource_id\": \"CHEMBL3338394\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [25226236], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"17341\"}], \"rcsb_id\": \"5DYW_1\"}}, \"interface_chains\": {\"chain1\": \"nan\", \"chain2\": \"nan\", \"assembly_chain1\": \"A\", \"assembly_chain2\": \"B\"}, \"enrichment_timestamp\": \"2025-12-23T18:08:05.553168\"}",
        "valueReference": {
          "@type": "PropertyValue",
          "name": "ParsedPDBMetadata",
          "value": {
            "resolution": 2.5,
            "experimentalMethod": null,
            "depositionDate": "2015-09-25T00:00:00+0000",
            "releaseDate": "2017-01-18T00:00:00+0000",
            "sourceOrganism": [
              "Homo sapiens"
            ],
            "spaceGroup": null,
            "rFactor": null,
            "entityCount": 11,
            "chainCount": 2,
            "uniqueSequences": 1,
            "isHomomer": true,
            "homomerType": "monomer"
          }
        }
      },
      {
        "@type": "PropertyValue",
        "name": "Resolution",
        "value": 2.5,
        "unitCode": "",
        "description": "X-ray crystallography resolution"
      },
      {
        "@type": "PropertyValue",
        "name": "SourceOrganism",
        "value": "Homo sapiens",
        "description": "Organism from which the protein was isolated"
      },
      {
        "@type": "PropertyValue",
        "name": "HomomericStructure",
        "value": true,
        "description": "This is a homomeric monomer"
      },
      {
        "@type": "PropertyValue",
        "name": "HomomerType",
        "value": "monomer",
        "description": "Type of homomeric assembly"
      },
      {
        "@type": "PropertyValue",
        "name": "ChainCount",
        "value": 2,
        "description": "Number of chains in the structure"
      },
      {
        "@type": "PropertyValue",
        "name": "UniqueSequenceCount",
        "value": 1,
        "description": "Number of unique amino acid sequences"
      },
      {
        "@type": "PropertyValue",
        "name": "Chain_A_Sequence",
        "value": "TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV",
        "description": "Amino acid sequence for chain A (length: 530)",
        "chainId": "A",
        "entityId": "1",
        "sequenceLength": 530
      },
      {
        "@type": "PropertyValue",
        "name": "Chain_B_Sequence",
        "value": "TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV",
        "description": "Amino acid sequence for chain B (length: 530)",
        "chainId": "B",
        "entityId": "1",
        "sequenceLength": 530
      },
      {
        "@type": "PropertyValue",
        "name": "PrimaryCitation",
        "value": "Development of an in-vivo active reversible butyrylcholinesterase inhibitor.",
        "description": "Primary publication for this structure"
      },
      {
        "@type": "PropertyValue",
        "name": "PublicationDOI",
        "value": "10.1038/srep39495",
        "description": "DOI of the primary publication"
      },
      {
        "@type": "PropertyValue",
        "name": "Entity_1",
        "value": "Chains: A, B, Length: 530",
        "description": "Entity 1 information"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterID",
        "value": "3BL8_1",
        "description": "Sequence cluster ID from BLASTClust analysis"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterSize",
        "value": 5,
        "description": "Number of interfaces in this cluster"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterMembers",
        "value": [
          "3BL8_1",
          "1SOM_1",
          "2HA7_1",
          "1XLU_1"
        ],
        "description": "List of other interfaces in the same cluster (excluding current interface)"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterMethod",
        "value": "BLASTClust sequence clustering",
        "description": "Method used for sequence-based clustering"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterMethodOptions",
        "value": "-S 25 -L 0.5 -b F",
        "description": "BLASTClust parameters used for sequence clustering"
      }
    ],
    "hasMolecularFunction": {
      "@type": "DefinedTerm",
      "name": "protein binding",
      "inDefinedTermSet": "http://purl.obolibrary.org/obo/GO_0005515"
    },
    "bioChemInteraction": {
      "@type": "Protein",
      "name": "Homodimer partner for interface 5DYW_1",
      "description": "Homodimer interaction partner in chain nan"
    }
  },
  "additionalProperty": [
    {
      "@type": "PropertyValue",
      "name": "InterfaceSource",
      "value": "QSalign",
      "description": "Source of interface ID: QSalign"
    },
    {
      "@type": "PropertyValue",
      "name": "physio",
      "value": false,
      "description": "Physiological (TRUE) or non-physiological (FALSE)"
    },
    {
      "@type": "PropertyValue",
      "name": "label",
      "value": 0,
      "description": "Numeric label (1=physio, 0=non-physio)"
    },
    {
      "@type": "PropertyValue",
      "name": "PDB_ID",
      "value": "5DYW",
      "description": "Protein Data Bank identifier"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain1",
      "value": "nan",
      "description": "First chain in interface"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain2",
      "value": "nan",
      "description": "Second chain in interface"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain1",
      "value": "nan",
      "description": "First chain in the interface (may be updated from assembly)"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain2",
      "value": "nan",
      "description": "Second chain in the interface (may be updated from assembly)"
    },
    {
      "@type": "PropertyValue",
      "name": "SymmetryOp1",
      "value": "nan",
      "description": "Symmetry operation for chain 1"
    },
    {
      "@type": "PropertyValue",
      "name": "SymmetryOp2",
      "value": "nan",
      "description": "Symmetry operation for chain 2"
    },
    {
      "@type": "PropertyValue",
      "name": "LabelChain1",
      "value": "A",
      "description": "First chain in the assembly interface"
    },
    {
      "@type": "PropertyValue",
      "name": "LabelChain2",
      "value": "B",
      "description": "Second chain in the assembly interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Buried Surface Area (BSA)",
      "value": 1427.99,
      "unitCode": "",
      "description": "Total buried surface area at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Atomic Contacts",
      "value": 47,
      "description": "Number of atomic contacts at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Gene",
      "value": "BCHE",
      "description": "Gene name associated with the protein"
    },
    {
      "@type": "PropertyValue",
      "name": "Superfamily",
      "value": "3.40.50.1820",
      "description": "Protein superfamily classification"
    },
    {
      "@type": "PropertyValue",
      "name": "Pfam",
      "value": "PF00135",
      "description": "Pfam domain classification"
    },
    {
      "@type": "PropertyValue",
      "name": "BSA Polar",
      "value": 779.18,
      "unitCode": "",
      "description": "Polar component of buried surface area"
    },
    {
      "@type": "PropertyValue",
      "name": "BSA Apolar",
      "value": 648.799999999996,
      "unitCode": "",
      "description": "Apolar component of buried surface area"
    },
    {
      "@type": "PropertyValue",
      "name": "Fraction Polar",
      "value": 0.54564807876806,
      "description": "Fraction of polar contacts at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Fraction Apolar",
      "value": 0.454344918381779,
      "description": "Fraction of apolar contacts at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterID",
      "value": "3BL8_1",
      "description": "Sequence cluster ID from BLASTClust analysis"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterSize",
      "value": 5,
      "description": "Number of interfaces in this cluster"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterMembers",
      "value": [
        "3BL8_1",
        "1SOM_1",
        "2HA7_1",
        "1XLU_1"
      ],
      "description": "List of other interfaces in the same cluster (excluding current interface)"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterMethod",
      "value": "BLASTClust sequence clustering",
      "description": "Method used for sequence-based clustering"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterMethodOptions",
      "value": "-S 25 -L 0.5 -b F",
      "description": "BLASTClust parameters used for sequence clustering"
    }
  ]
}